Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review

Sharing of equipment used for injecting drug use (IDU) is a substantial cause of disease burden and a contributor to blood-borne virus transmission. We did a global multistage systematic review to identify the prevalence of IDU among people aged 15–64 years; sociodemographic characteristics of and r...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:The Lancet global health Ročník 5; číslo 12; s. e1192 - e1207
Hlavní autoři: Degenhardt, Louisa, Peacock, Amy, Colledge, Samantha, Leung, Janni, Grebely, Jason, Vickerman, Peter, Stone, Jack, Cunningham, Evan B, Trickey, Adam, Dumchev, Kostyantyn, Lynskey, Michael, Griffiths, Paul, Mattick, Richard P, Hickman, Matthew, Larney, Sarah
Médium: Journal Article
Jazyk:angličtina
Vydáno: England Elsevier Ltd 01.12.2017
Elsevier
Témata:
Global Health
Hepatitis B - epidemiology
Hepatitis B - transmission
Hepatitis C - epidemiology
Hepatitis C - transmission
HIV Infections - epidemiology
HIV Infections - transmission
Humans
Risk Factors
Sexual Behavior
Substance Abuse, Intravenous - complications
Substance Abuse, Intravenous - epidemiology
Substance Abuse, Intravenous - psychology
ISSN:2214-109X, 2214-109X
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Sharing of equipment used for injecting drug use (IDU) is a substantial cause of disease burden and a contributor to blood-borne virus transmission. We did a global multistage systematic review to identify the prevalence of IDU among people aged 15–64 years; sociodemographic characteristics of and risk factors for people who inject drugs (PWID); and the prevalence of HIV, hepatitis C virus (HCV), and hepatitis B virus (HBV) among PWID. Consistent with the GATHER and PRISMA guidelines and without language restrictions, we systematically searched peer-reviewed databases (MEDLINE, Embase, and PsycINFO; articles published since 2008, latest searches in June, 2017), searched the grey literature (websites and databases, searches between April and August, 2016), and disseminated data requests to international experts and agencies (requests sent in October, 2016). We searched for data on IDU prevalence, characteristics of PWID, including gender, age, and sociodemographic and risk characteristics, and the prevalence of HIV, HCV, and HBV among PWID. Eligible data on prevalence of IDU, HIV antibody, HBsAg, and HCV antibody among PWID were selected and, where multiple estimates were available, pooled for each country via random effects meta-analysis. So too were eligible data on percentage of PWID who were female; younger than 25 years; recently homeless; ever arrested; ever incarcerated; who had recently engaged in sex work, sexual risk, or injecting risk; and whose main drugs injected were opioids or stimulants. We generated regional and global estimates in line with previous global reviews. We reviewed 55 671 papers and reports, and extracted data from 1147 eligible records. Evidence of IDU was recorded in 179 of 206 countries or territories, which cover 99% of the population aged 15–64 years, an increase of 31 countries (mostly in sub-Saharan Africa and the Pacific Islands) since a review in 2008. IDU prevalence estimates were identified in 83 countries. We estimate that there are 15·6 million (95% uncertainty interval [UI] 10·2–23·7 million) PWID aged 15–64 years globally, with 3·2 million (1·6–5·1 million) women and 12·5 million (7·5–18·4 million) men. Gender composition varied by location: women were estimated to comprise 30·0% (95% UI 28·5–31·5) of PWID in North America and 33·4% (31·0–35·6) in Australasia, compared with 3·1% (2·1–4·1) in south Asia. Globally, we estimate that 17·8% (10·8–24·8) of PWID are living with HIV, 52·3% (42·4–62·1) are HCV-antibody positive, and 9·1% (5·1–13·2) are HBV surface antigen positive; there is substantial geographic variation in these levels. Globally, we estimate 82·9% (76·6–88·9) of PWID mainly inject opioids and 33·0% (24·3–42·0) mainly inject stimulants. We estimate that 27·9% (20·9–36·8) of PWID globally are younger than 25 years, 21·7% (15·8–27·9) had recently (within the past year) experienced homelessness or unstable housing, and 57·9% (50·5–65·2) had a history of incarceration. We identified evidence of IDU in more countries than in 2008, with the new countries largely consisting of low-income and middle-income countries in Africa. Across all countries, a substantial number of PWID are living with HIV and HCV and are exposed to multiple adverse risk environments that increase health harms. Australian National Drug and Alcohol Research Centre, Australian National Health and Medical Research Council, Open Society Foundation, World Health Organization, the Global Fund, and UNAIDS.
AbstractList Sharing of equipment used for injecting drug use (IDU) is a substantial cause of disease burden and a contributor to blood-borne virus transmission. We did a global multistage systematic review to identify the prevalence of IDU among people aged 15–64 years; sociodemographic characteristics of and risk factors for people who inject drugs (PWID); and the prevalence of HIV, hepatitis C virus (HCV), and hepatitis B virus (HBV) among PWID. Consistent with the GATHER and PRISMA guidelines and without language restrictions, we systematically searched peer-reviewed databases (MEDLINE, Embase, and PsycINFO; articles published since 2008, latest searches in June, 2017), searched the grey literature (websites and databases, searches between April and August, 2016), and disseminated data requests to international experts and agencies (requests sent in October, 2016). We searched for data on IDU prevalence, characteristics of PWID, including gender, age, and sociodemographic and risk characteristics, and the prevalence of HIV, HCV, and HBV among PWID. Eligible data on prevalence of IDU, HIV antibody, HBsAg, and HCV antibody among PWID were selected and, where multiple estimates were available, pooled for each country via random effects meta-analysis. So too were eligible data on percentage of PWID who were female; younger than 25 years; recently homeless; ever arrested; ever incarcerated; who had recently engaged in sex work, sexual risk, or injecting risk; and whose main drugs injected were opioids or stimulants. We generated regional and global estimates in line with previous global reviews. We reviewed 55 671 papers and reports, and extracted data from 1147 eligible records. Evidence of IDU was recorded in 179 of 206 countries or territories, which cover 99% of the population aged 15–64 years, an increase of 31 countries (mostly in sub-Saharan Africa and the Pacific Islands) since a review in 2008. IDU prevalence estimates were identified in 83 countries. We estimate that there are 15·6 million (95% uncertainty interval [UI] 10·2–23·7 million) PWID aged 15–64 years globally, with 3·2 million (1·6–5·1 million) women and 12·5 million (7·5–18·4 million) men. Gender composition varied by location: women were estimated to comprise 30·0% (95% UI 28·5–31·5) of PWID in North America and 33·4% (31·0–35·6) in Australasia, compared with 3·1% (2·1–4·1) in south Asia. Globally, we estimate that 17·8% (10·8–24·8) of PWID are living with HIV, 52·3% (42·4–62·1) are HCV-antibody positive, and 9·1% (5·1–13·2) are HBV surface antigen positive; there is substantial geographic variation in these levels. Globally, we estimate 82·9% (76·6–88·9) of PWID mainly inject opioids and 33·0% (24·3–42·0) mainly inject stimulants. We estimate that 27·9% (20·9–36·8) of PWID globally are younger than 25 years, 21·7% (15·8–27·9) had recently (within the past year) experienced homelessness or unstable housing, and 57·9% (50·5–65·2) had a history of incarceration. We identified evidence of IDU in more countries than in 2008, with the new countries largely consisting of low-income and middle-income countries in Africa. Across all countries, a substantial number of PWID are living with HIV and HCV and are exposed to multiple adverse risk environments that increase health harms. Australian National Drug and Alcohol Research Centre, Australian National Health and Medical Research Council, Open Society Foundation, World Health Organization, the Global Fund, and UNAIDS.
Background: Sharing of equipment used for injecting drug use (IDU) is a substantial cause of disease burden and a contributor to blood-borne virus transmission. We did a global multistage systematic review to identify the prevalence of IDU among people aged 15–64 years; sociodemographic characteristics of and risk factors for people who inject drugs (PWID); and the prevalence of HIV, hepatitis C virus (HCV), and hepatitis B virus (HBV) among PWID. Methods: Consistent with the GATHER and PRISMA guidelines and without language restrictions, we systematically searched peer-reviewed databases (MEDLINE, Embase, and PsycINFO; articles published since 2008, latest searches in June, 2017), searched the grey literature (websites and databases, searches between April and August, 2016), and disseminated data requests to international experts and agencies (requests sent in October, 2016). We searched for data on IDU prevalence, characteristics of PWID, including gender, age, and sociodemographic and risk characteristics, and the prevalence of HIV, HCV, and HBV among PWID. Eligible data on prevalence of IDU, HIV antibody, HBsAg, and HCV antibody among PWID were selected and, where multiple estimates were available, pooled for each country via random effects meta-analysis. So too were eligible data on percentage of PWID who were female; younger than 25 years; recently homeless; ever arrested; ever incarcerated; who had recently engaged in sex work, sexual risk, or injecting risk; and whose main drugs injected were opioids or stimulants. We generated regional and global estimates in line with previous global reviews. Findings: We reviewed 55 671 papers and reports, and extracted data from 1147 eligible records. Evidence of IDU was recorded in 179 of 206 countries or territories, which cover 99% of the population aged 15–64 years, an increase of 31 countries (mostly in sub-Saharan Africa and the Pacific Islands) since a review in 2008. IDU prevalence estimates were identified in 83 countries. We estimate that there are 15·6 million (95% uncertainty interval [UI] 10·2–23·7 million) PWID aged 15–64 years globally, with 3·2 million (1·6–5·1 million) women and 12·5 million (7·5–18·4 million) men. Gender composition varied by location: women were estimated to comprise 30·0% (95% UI 28·5–31·5) of PWID in North America and 33·4% (31·0–35·6) in Australasia, compared with 3·1% (2·1–4·1) in south Asia. Globally, we estimate that 17·8% (10·8–24·8) of PWID are living with HIV, 52·3% (42·4–62·1) are HCV-antibody positive, and 9·1% (5·1–13·2) are HBV surface antigen positive; there is substantial geographic variation in these levels. Globally, we estimate 82·9% (76·6–88·9) of PWID mainly inject opioids and 33·0% (24·3–42·0) mainly inject stimulants. We estimate that 27·9% (20·9–36·8) of PWID globally are younger than 25 years, 21·7% (15·8–27·9) had recently (within the past year) experienced homelessness or unstable housing, and 57·9% (50·5–65·2) had a history of incarceration. Interpretation: We identified evidence of IDU in more countries than in 2008, with the new countries largely consisting of low-income and middle-income countries in Africa. Across all countries, a substantial number of PWID are living with HIV and HCV and are exposed to multiple adverse risk environments that increase health harms. Funding: Australian National Drug and Alcohol Research Centre, Australian National Health and Medical Research Council, Open Society Foundation, World Health Organization, the Global Fund, and UNAIDS.
Sharing of equipment used for injecting drug use (IDU) is a substantial cause of disease burden and a contributor to blood-borne virus transmission. We did a global multistage systematic review to identify the prevalence of IDU among people aged 15-64 years; sociodemographic characteristics of and risk factors for people who inject drugs (PWID); and the prevalence of HIV, hepatitis C virus (HCV), and hepatitis B virus (HBV) among PWID.BACKGROUNDSharing of equipment used for injecting drug use (IDU) is a substantial cause of disease burden and a contributor to blood-borne virus transmission. We did a global multistage systematic review to identify the prevalence of IDU among people aged 15-64 years; sociodemographic characteristics of and risk factors for people who inject drugs (PWID); and the prevalence of HIV, hepatitis C virus (HCV), and hepatitis B virus (HBV) among PWID.Consistent with the GATHER and PRISMA guidelines and without language restrictions, we systematically searched peer-reviewed databases (MEDLINE, Embase, and PsycINFO; articles published since 2008, latest searches in June, 2017), searched the grey literature (websites and databases, searches between April and August, 2016), and disseminated data requests to international experts and agencies (requests sent in October, 2016). We searched for data on IDU prevalence, characteristics of PWID, including gender, age, and sociodemographic and risk characteristics, and the prevalence of HIV, HCV, and HBV among PWID. Eligible data on prevalence of IDU, HIV antibody, HBsAg, and HCV antibody among PWID were selected and, where multiple estimates were available, pooled for each country via random effects meta-analysis. So too were eligible data on percentage of PWID who were female; younger than 25 years; recently homeless; ever arrested; ever incarcerated; who had recently engaged in sex work, sexual risk, or injecting risk; and whose main drugs injected were opioids or stimulants. We generated regional and global estimates in line with previous global reviews.METHODSConsistent with the GATHER and PRISMA guidelines and without language restrictions, we systematically searched peer-reviewed databases (MEDLINE, Embase, and PsycINFO; articles published since 2008, latest searches in June, 2017), searched the grey literature (websites and databases, searches between April and August, 2016), and disseminated data requests to international experts and agencies (requests sent in October, 2016). We searched for data on IDU prevalence, characteristics of PWID, including gender, age, and sociodemographic and risk characteristics, and the prevalence of HIV, HCV, and HBV among PWID. Eligible data on prevalence of IDU, HIV antibody, HBsAg, and HCV antibody among PWID were selected and, where multiple estimates were available, pooled for each country via random effects meta-analysis. So too were eligible data on percentage of PWID who were female; younger than 25 years; recently homeless; ever arrested; ever incarcerated; who had recently engaged in sex work, sexual risk, or injecting risk; and whose main drugs injected were opioids or stimulants. We generated regional and global estimates in line with previous global reviews.We reviewed 55 671 papers and reports, and extracted data from 1147 eligible records. Evidence of IDU was recorded in 179 of 206 countries or territories, which cover 99% of the population aged 15-64 years, an increase of 31 countries (mostly in sub-Saharan Africa and the Pacific Islands) since a review in 2008. IDU prevalence estimates were identified in 83 countries. We estimate that there are 15·6 million (95% uncertainty interval [UI] 10·2-23·7 million) PWID aged 15-64 years globally, with 3·2 million (1·6-5·1 million) women and 12·5 million (7·5-18·4 million) men. Gender composition varied by location: women were estimated to comprise 30·0% (95% UI 28·5-31·5) of PWID in North America and 33·4% (31·0-35·6) in Australasia, compared with 3·1% (2·1-4·1) in south Asia. Globally, we estimate that 17·8% (10·8-24·8) of PWID are living with HIV, 52·3% (42·4-62·1) are HCV-antibody positive, and 9·0% (5·1-13·2) are HBV surface antigen positive; there is substantial geographic variation in these levels. Globally, we estimate 82·9% (76·6-88·9) of PWID mainly inject opioids and 33·0% (24·3-42·0) mainly inject stimulants. We estimate that 27·9% (20·9-36·8) of PWID globally are younger than 25 years, 21·7% (15·8-27·9) had recently (within the past year) experienced homelessness or unstable housing, and 57·9% (50·5-65·2) had a history of incarceration.FINDINGSWe reviewed 55 671 papers and reports, and extracted data from 1147 eligible records. Evidence of IDU was recorded in 179 of 206 countries or territories, which cover 99% of the population aged 15-64 years, an increase of 31 countries (mostly in sub-Saharan Africa and the Pacific Islands) since a review in 2008. IDU prevalence estimates were identified in 83 countries. We estimate that there are 15·6 million (95% uncertainty interval [UI] 10·2-23·7 million) PWID aged 15-64 years globally, with 3·2 million (1·6-5·1 million) women and 12·5 million (7·5-18·4 million) men. Gender composition varied by location: women were estimated to comprise 30·0% (95% UI 28·5-31·5) of PWID in North America and 33·4% (31·0-35·6) in Australasia, compared with 3·1% (2·1-4·1) in south Asia. Globally, we estimate that 17·8% (10·8-24·8) of PWID are living with HIV, 52·3% (42·4-62·1) are HCV-antibody positive, and 9·0% (5·1-13·2) are HBV surface antigen positive; there is substantial geographic variation in these levels. Globally, we estimate 82·9% (76·6-88·9) of PWID mainly inject opioids and 33·0% (24·3-42·0) mainly inject stimulants. We estimate that 27·9% (20·9-36·8) of PWID globally are younger than 25 years, 21·7% (15·8-27·9) had recently (within the past year) experienced homelessness or unstable housing, and 57·9% (50·5-65·2) had a history of incarceration.We identified evidence of IDU in more countries than in 2008, with the new countries largely consisting of low-income and middle-income countries in Africa. Across all countries, a substantial number of PWID are living with HIV and HCV and are exposed to multiple adverse risk environments that increase health harms.INTERPRETATIONWe identified evidence of IDU in more countries than in 2008, with the new countries largely consisting of low-income and middle-income countries in Africa. Across all countries, a substantial number of PWID are living with HIV and HCV and are exposed to multiple adverse risk environments that increase health harms.Australian National Drug and Alcohol Research Centre, Australian National Health and Medical Research Council, Open Society Foundation, World Health Organization, the Global Fund, and UNAIDS.FUNDINGAustralian National Drug and Alcohol Research Centre, Australian National Health and Medical Research Council, Open Society Foundation, World Health Organization, the Global Fund, and UNAIDS.
Sharing of equipment used for injecting drug use (IDU) is a substantial cause of disease burden and a contributor to blood-borne virus transmission. We did a global multistage systematic review to identify the prevalence of IDU among people aged 15-64 years; sociodemographic characteristics of and risk factors for people who inject drugs (PWID); and the prevalence of HIV, hepatitis C virus (HCV), and hepatitis B virus (HBV) among PWID. Consistent with the GATHER and PRISMA guidelines and without language restrictions, we systematically searched peer-reviewed databases (MEDLINE, Embase, and PsycINFO; articles published since 2008, latest searches in June, 2017), searched the grey literature (websites and databases, searches between April and August, 2016), and disseminated data requests to international experts and agencies (requests sent in October, 2016). We searched for data on IDU prevalence, characteristics of PWID, including gender, age, and sociodemographic and risk characteristics, and the prevalence of HIV, HCV, and HBV among PWID. Eligible data on prevalence of IDU, HIV antibody, HBsAg, and HCV antibody among PWID were selected and, where multiple estimates were available, pooled for each country via random effects meta-analysis. So too were eligible data on percentage of PWID who were female; younger than 25 years; recently homeless; ever arrested; ever incarcerated; who had recently engaged in sex work, sexual risk, or injecting risk; and whose main drugs injected were opioids or stimulants. We generated regional and global estimates in line with previous global reviews. We reviewed 55 671 papers and reports, and extracted data from 1147 eligible records. Evidence of IDU was recorded in 179 of 206 countries or territories, which cover 99% of the population aged 15-64 years, an increase of 31 countries (mostly in sub-Saharan Africa and the Pacific Islands) since a review in 2008. IDU prevalence estimates were identified in 83 countries. We estimate that there are 15·6 million (95% uncertainty interval [UI] 10·2-23·7 million) PWID aged 15-64 years globally, with 3·2 million (1·6-5·1 million) women and 12·5 million (7·5-18·4 million) men. Gender composition varied by location: women were estimated to comprise 30·0% (95% UI 28·5-31·5) of PWID in North America and 33·4% (31·0-35·6) in Australasia, compared with 3·1% (2·1-4·1) in south Asia. Globally, we estimate that 17·8% (10·8-24·8) of PWID are living with HIV, 52·3% (42·4-62·1) are HCV-antibody positive, and 9·0% (5·1-13·2) are HBV surface antigen positive; there is substantial geographic variation in these levels. Globally, we estimate 82·9% (76·6-88·9) of PWID mainly inject opioids and 33·0% (24·3-42·0) mainly inject stimulants. We estimate that 27·9% (20·9-36·8) of PWID globally are younger than 25 years, 21·7% (15·8-27·9) had recently (within the past year) experienced homelessness or unstable housing, and 57·9% (50·5-65·2) had a history of incarceration. We identified evidence of IDU in more countries than in 2008, with the new countries largely consisting of low-income and middle-income countries in Africa. Across all countries, a substantial number of PWID are living with HIV and HCV and are exposed to multiple adverse risk environments that increase health harms. Australian National Drug and Alcohol Research Centre, Australian National Health and Medical Research Council, Open Society Foundation, World Health Organization, the Global Fund, and UNAIDS.
Author Mattick, Richard P
Trickey, Adam
Larney, Sarah
Vickerman, Peter
Grebely, Jason
Dumchev, Kostyantyn
Hickman, Matthew
Cunningham, Evan B
Stone, Jack
Lynskey, Michael
Degenhardt, Louisa
Colledge, Samantha
Griffiths, Paul
Peacock, Amy
Leung, Janni
AuthorAffiliation f National Addiction Centre, King's College London, London, UK
g European Monitoring Centre on Drugs and Drug Addiction, Lisbon, Portugal
c Kirby Institute, UNSW Sydney, Sydney, NSW, Australia
a National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, NSW, Australia
e Ukrainian Institute for Public Health Policy, Kiev, Ukraine
d Population Health Science, Bristol Medical School, University of Bristol, Bristol, UK
b School of Public Health, Faculty of Medicine, University of Queensland, Herston, QLD, Australia
AuthorAffiliation_xml – name: d Population Health Science, Bristol Medical School, University of Bristol, Bristol, UK
– name: e Ukrainian Institute for Public Health Policy, Kiev, Ukraine
– name: f National Addiction Centre, King's College London, London, UK
– name: c Kirby Institute, UNSW Sydney, Sydney, NSW, Australia
– name: b School of Public Health, Faculty of Medicine, University of Queensland, Herston, QLD, Australia
– name: a National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, NSW, Australia
– name: g European Monitoring Centre on Drugs and Drug Addiction, Lisbon, Portugal
Author_xml – sequence: 1
  givenname: Louisa
  surname: Degenhardt
  fullname: Degenhardt, Louisa
  email: l.degenhardt@unsw.edu.au
  organization: National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, NSW, Australia
– sequence: 2
  givenname: Amy
  surname: Peacock
  fullname: Peacock, Amy
  organization: National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, NSW, Australia
– sequence: 3
  givenname: Samantha
  surname: Colledge
  fullname: Colledge, Samantha
  organization: National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, NSW, Australia
– sequence: 4
  givenname: Janni
  surname: Leung
  fullname: Leung, Janni
  organization: School of Public Health, Faculty of Medicine, University of Queensland, Herston, QLD, Australia
– sequence: 5
  givenname: Jason
  surname: Grebely
  fullname: Grebely, Jason
  organization: Kirby Institute, UNSW Sydney, Sydney, NSW, Australia
– sequence: 6
  givenname: Peter
  surname: Vickerman
  fullname: Vickerman, Peter
  organization: Population Health Science, Bristol Medical School, University of Bristol, Bristol, UK
– sequence: 7
  givenname: Jack
  surname: Stone
  fullname: Stone, Jack
  organization: Population Health Science, Bristol Medical School, University of Bristol, Bristol, UK
– sequence: 8
  givenname: Evan B
  surname: Cunningham
  fullname: Cunningham, Evan B
  organization: Kirby Institute, UNSW Sydney, Sydney, NSW, Australia
– sequence: 9
  givenname: Adam
  surname: Trickey
  fullname: Trickey, Adam
  organization: Population Health Science, Bristol Medical School, University of Bristol, Bristol, UK
– sequence: 10
  givenname: Kostyantyn
  surname: Dumchev
  fullname: Dumchev, Kostyantyn
  organization: Ukrainian Institute for Public Health Policy, Kiev, Ukraine
– sequence: 11
  givenname: Michael
  surname: Lynskey
  fullname: Lynskey, Michael
  organization: National Addiction Centre, King's College London, London, UK
– sequence: 12
  givenname: Paul
  surname: Griffiths
  fullname: Griffiths, Paul
  organization: European Monitoring Centre on Drugs and Drug Addiction, Lisbon, Portugal
– sequence: 13
  givenname: Richard P
  surname: Mattick
  fullname: Mattick, Richard P
  organization: National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, NSW, Australia
– sequence: 14
  givenname: Matthew
  surname: Hickman
  fullname: Hickman, Matthew
  organization: Population Health Science, Bristol Medical School, University of Bristol, Bristol, UK
– sequence: 15
  givenname: Sarah
  surname: Larney
  fullname: Larney, Sarah
  organization: National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, NSW, Australia
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29074409$$D View this record in MEDLINE/PubMed
BookMark eNqNkt9u0zAUxiM0xMbYI4B8OSQKcZzEMRMgqGCtNIkLYOLOOnFOUhcnDnayqc_ES-L-oVp3MyLLiezv_I6d73saHXW2wyh6TuPXNKb5m29JQtMJjcXPc8pfspjxbMIeRSf75aM738fRmffLODxCsITzJ9FxImKeprE4if5cGluCIb3DGzDYKSS2Jrpbohp015DKjQ0ZPRLoKuKt0rbC1jYO-oVWRC3AgRrQaT9o5TeiQ9Jsfv2KzD6Fab03m14HNunR9gbJ7cLuOm3a-LcESDuaIcCgQeJXfsAWApgEpMbbZ9HjGozHs937NPrx5fP36Wxy9fVyPv14NVF5xoZJyWgeJ5QqpCmvWY4sr4UoVakKDuH-yONacQCkDIskrwHDKNMSK15ktcjZaTTfcisLS9k73YJbSQtabhasayS4cCyDEoo0ZwkTWVZAimFigjGVVIlKmUhzHljvt6x-LFusFHaDA3MAPdzp9EI29kZmecE4KwLgfAdw9veIfpCt9gqNgQ7t6CUVGU_zgsdJkL6422vf5J_bQZBtBcpZ7x3WewmN5TpYchMsuU6NpFxugiVZqLu4V6f0EIyx6yNr82D1h201Bs-Cj056pdf5qLQL3oefqh8kvLtHUEZ3WoH5hav_qP8Lx7r95w
CitedBy_id crossref_primary_10_1016_j_ssmmh_2022_100095
crossref_primary_10_1111_ner_13291
crossref_primary_10_1016_j_dadr_2023_100168
crossref_primary_10_1016_j_drugpo_2020_102923
crossref_primary_10_1080_09540121_2025_2530411
crossref_primary_10_1521_aeap_2018_30_3_225
crossref_primary_10_1111_liv_15237
crossref_primary_10_1016_j_drugalcdep_2020_108133
crossref_primary_10_1002_cld_1023
crossref_primary_10_1371_journal_pone_0316668
crossref_primary_10_1111_dar_13001
crossref_primary_10_1111_apt_15222
crossref_primary_10_1111_tme_12660
crossref_primary_10_1002_jcla_22876
crossref_primary_10_1097_QAD_0000000000003670
crossref_primary_10_1016_j_lana_2024_100679
crossref_primary_10_1111_jnu_12486
crossref_primary_10_1186_s13011_025_00645_x
crossref_primary_10_3389_fpsyt_2020_573150
crossref_primary_10_3389_fpsyt_2023_1227216
crossref_primary_10_1177_11782218231157340
crossref_primary_10_1007_s10792_021_01709_0
crossref_primary_10_1016_j_jhep_2018_09_030
crossref_primary_10_1080_00952990_2022_2091451
crossref_primary_10_1186_s12939_021_01420_7
crossref_primary_10_1016_j_drugalcdep_2020_108121
crossref_primary_10_1007_s11469_023_01034_w
crossref_primary_10_1111_liv_14399
crossref_primary_10_1016_j_dadr_2023_100151
crossref_primary_10_1111_jvh_13820
crossref_primary_10_1186_s12954_020_00429_5
crossref_primary_10_3390_ijerph20010501
crossref_primary_10_1186_s12889_023_17587_3
crossref_primary_10_1007_s11904_022_00619_9
crossref_primary_10_1136_bmjopen_2022_067608
crossref_primary_10_1097_AIA_0000000000000276
crossref_primary_10_3390_v16111792
crossref_primary_10_1080_15332640_2022_2080785
crossref_primary_10_1136_bmjopen_2021_053394
crossref_primary_10_1186_s12954_019_0290_x
crossref_primary_10_1038_s41572_019_0137_5
crossref_primary_10_1111_dar_13016
crossref_primary_10_1136_bmjopen_2020_045282
crossref_primary_10_1016_S2468_1253_22_00275_8
crossref_primary_10_1016_j_jhep_2021_09_038
crossref_primary_10_1007_s10461_022_03851_x
crossref_primary_10_1371_journal_pone_0302471
crossref_primary_10_1016_j_drugpo_2018_02_001
crossref_primary_10_1016_j_drugpo_2020_102707
crossref_primary_10_1111_jvh_12987
crossref_primary_10_1016_j_jval_2024_03_005
crossref_primary_10_1002_jia2_25777
crossref_primary_10_1016_j_drugpo_2020_102710
crossref_primary_10_1002_hsr2_290
crossref_primary_10_1016_j_sleh_2024_07_008
crossref_primary_10_3390_pathogens13050367
crossref_primary_10_1016_j_arcmed_2022_09_004
crossref_primary_10_1016_j_meegid_2018_05_028
crossref_primary_10_1080_10826084_2022_2083171
crossref_primary_10_1016_j_idc_2018_02_003
crossref_primary_10_1111_add_16193
crossref_primary_10_1111_liv_15469
crossref_primary_10_1007_s00705_020_04716_1
crossref_primary_10_3390_antibiotics13080782
crossref_primary_10_1186_s13643_020_01542_z
crossref_primary_10_3389_fpubh_2024_1282575
crossref_primary_10_1016_j_etdah_2022_100046
crossref_primary_10_1001_jamanetworkopen_2020_20802
crossref_primary_10_1177_00914509211060723
crossref_primary_10_1186_s12916_018_1162_z
crossref_primary_10_1002_hsr2_229
crossref_primary_10_1016_j_jtbi_2018_11_013
crossref_primary_10_1016_j_drugpo_2018_03_022
crossref_primary_10_1016_j_lanwpc_2023_100718
crossref_primary_10_1097_OLQ_0000000000001484
crossref_primary_10_1186_s12879_019_4620_0
crossref_primary_10_1111_dar_13681
crossref_primary_10_1111_dar_13442
crossref_primary_10_1097_QAD_0000000000002387
crossref_primary_10_1038_s41575_024_00967_4
crossref_primary_10_1002_cld_1061
crossref_primary_10_1016_j_drugpo_2018_03_023
crossref_primary_10_1080_02791072_2019_1567960
crossref_primary_10_3390_diagnostics11071197
crossref_primary_10_1186_s12879_020_05359_y
crossref_primary_10_1111_dar_13688
crossref_primary_10_1186_s12888_025_07223_2
crossref_primary_10_1016_j_drugpo_2018_03_018
crossref_primary_10_1186_s12879_019_4655_2
crossref_primary_10_2807_1560_7917_ES_2025_30_30_2500007
crossref_primary_10_1002_kjm2_12788
crossref_primary_10_1016_j_drugpo_2018_10_004
crossref_primary_10_1371_journal_pone_0237772
crossref_primary_10_4103_njhs_njhs_7_22
crossref_primary_10_1038_s41598_022_24459_0
crossref_primary_10_1177_00333549221099323
crossref_primary_10_1016_j_jns_2020_116719
crossref_primary_10_1089_aid_2020_0050
crossref_primary_10_1111_add_16145
crossref_primary_10_1007_s10461_022_03777_4
crossref_primary_10_1002_jia2_25730
crossref_primary_10_1002_jia2_25736
crossref_primary_10_1016_j_drugpo_2021_103285
crossref_primary_10_1016_S2468_1253_22_00175_3
crossref_primary_10_1080_14760584_2020_1813577
crossref_primary_10_1186_s12889_020_8294_8
crossref_primary_10_1186_s12889_021_11783_9
crossref_primary_10_1186_s12879_020_05357_0
crossref_primary_10_1016_j_dadr_2023_100178
crossref_primary_10_1016_j_drugalcdep_2019_107816
crossref_primary_10_1038_s41598_025_94867_5
crossref_primary_10_1007_s10943_024_02069_6
crossref_primary_10_1186_s12879_022_07036_8
crossref_primary_10_1016_j_jsat_2020_108229
crossref_primary_10_1111_liv_15266
crossref_primary_10_1136_bmjgh_2019_001560
crossref_primary_10_1136_bmjopen_2018_026811
crossref_primary_10_1055_a_1777_6112
crossref_primary_10_2105_AJPH_2019_305379
crossref_primary_10_1186_s12889_020_09012_w
crossref_primary_10_1016_S2352_3018_18_30292_3
crossref_primary_10_1186_s13244_020_00903_5
crossref_primary_10_1186_s40249_023_01056_5
crossref_primary_10_1016_j_drugpo_2021_103297
crossref_primary_10_1038_s41598_020_80869_y
crossref_primary_10_1186_s12954_023_00910_x
crossref_primary_10_3748_wjg_v27_i31_5219
crossref_primary_10_1007_s11356_022_19770_2
crossref_primary_10_3390_ijerph191610382
crossref_primary_10_1016_S1473_3099_19_30264_6
crossref_primary_10_1016_j_addbeh_2021_107125
crossref_primary_10_1016_j_jsat_2021_108519
crossref_primary_10_1111_apt_16953
crossref_primary_10_2147_IJWH_S448147
crossref_primary_10_1186_s12879_024_09124_3
crossref_primary_10_1016_j_respe_2022_08_007
crossref_primary_10_3390_v14071548
crossref_primary_10_13105_wjma_v10_i3_99
crossref_primary_10_1016_j_drugpo_2021_103469
crossref_primary_10_1016_S2352_3018_19_30036_0
crossref_primary_10_3390_v14071541
crossref_primary_10_1186_s12954_024_01119_2
crossref_primary_10_1093_jalm_jfae035
crossref_primary_10_1371_journal_pone_0243106
crossref_primary_10_1089_can_2019_0104
crossref_primary_10_1186_s12954_021_00513_4
crossref_primary_10_1080_10550887_2020_1781346
crossref_primary_10_56786_PHWR_2025_18_33_2
crossref_primary_10_1080_10852352_2021_1915733
crossref_primary_10_1186_s43045_024_00450_5
crossref_primary_10_1016_j_ijregi_2022_08_007
crossref_primary_10_1038_s41598_024_80289_2
crossref_primary_10_1080_10530789_2021_1908487
crossref_primary_10_1111_jvh_13662
crossref_primary_10_1186_s13011_023_00557_8
crossref_primary_10_1097_ADM_0000000000000539
crossref_primary_10_1016_j_drugpo_2024_104387
crossref_primary_10_1080_08897077_2022_2028701
crossref_primary_10_14309_ajg_0000000000000651
crossref_primary_10_1038_s41598_019_42810_w
crossref_primary_10_36290_int_2019_049
crossref_primary_10_3389_fncir_2021_752420
crossref_primary_10_1111_jvh_13677
crossref_primary_10_3390_v16060971
crossref_primary_10_1136_bmjopen_2024_092510
crossref_primary_10_4254_wjh_v14_i1_1
crossref_primary_10_1111_add_14849
crossref_primary_10_1016_j_drugpo_2021_103482
crossref_primary_10_1007_s10461_019_02680_9
crossref_primary_10_1038_s41598_024_51336_9
crossref_primary_10_1111_add_14853
crossref_primary_10_1016_S1473_3099_20_30051_7
crossref_primary_10_5812_hepatmon_62030
crossref_primary_10_3390_medicina59091577
crossref_primary_10_3390_ijerph17072401
crossref_primary_10_1007_s10389_020_01221_2
crossref_primary_10_1093_cid_ciz063
crossref_primary_10_1016_j_drugpo_2021_103255
crossref_primary_10_1016_j_drugpo_2022_103710
crossref_primary_10_1111_jvh_13447
crossref_primary_10_1016_j_drugpo_2021_103252
crossref_primary_10_1080_09540121_2024_2372730
crossref_primary_10_1136_bmjopen_2019_034554
crossref_primary_10_1111_add_14820
crossref_primary_10_1016_j_drugpo_2021_103418
crossref_primary_10_1016_j_drugpo_2021_103419
crossref_primary_10_1038_s43856_023_00292_y
crossref_primary_10_1093_ofid_ofab325
crossref_primary_10_1016_j_drugpo_2021_103421
crossref_primary_10_1093_jalm_jfae075
crossref_primary_10_1007_s13337_019_00553_2
crossref_primary_10_1186_s13011_022_00491_1
crossref_primary_10_1016_j_drugpo_2021_103424
crossref_primary_10_1016_j_jhep_2019_10_018
crossref_primary_10_1136_bmjopen_2020_046957
crossref_primary_10_1093_cid_ciac246
crossref_primary_10_1186_s12954_021_00511_6
crossref_primary_10_1186_s12954_019_0281_y
crossref_primary_10_1111_add_14830
crossref_primary_10_1111_imj_14139
crossref_primary_10_1111_liv_15446
crossref_primary_10_1093_infdis_jiad138
crossref_primary_10_1080_14787210_2018_1505502
crossref_primary_10_1016_j_lanwpc_2022_100603
crossref_primary_10_1111_sdi_12882
crossref_primary_10_1016_j_dadr_2025_100355
crossref_primary_10_1016_S0140_6736_18_31070_5
crossref_primary_10_1016_j_drugpo_2022_103771
crossref_primary_10_1186_s13031_022_00467_9
crossref_primary_10_1097_COH_0000000000000571
crossref_primary_10_2196_54015
crossref_primary_10_7759_cureus_85719
crossref_primary_10_1016_j_drugpo_2021_103205
crossref_primary_10_1177_0844562120979577
crossref_primary_10_1016_j_josat_2024_209582
crossref_primary_10_1186_s13011_022_00438_6
crossref_primary_10_1111_jvh_13630
crossref_primary_10_1186_s12889_024_20299_x
crossref_primary_10_1097_QCO_0000000000000801
crossref_primary_10_1093_cid_ciad319
crossref_primary_10_1186_s12954_019_0324_4
crossref_primary_10_1016_j_drugpo_2021_103209
crossref_primary_10_1080_10826084_2019_1683198
crossref_primary_10_1186_s12954_021_00579_0
crossref_primary_10_1097_MCG_0000000000001532
crossref_primary_10_1007_s10461_021_03325_6
crossref_primary_10_1111_jvh_13647
crossref_primary_10_1177_21501319231161208
crossref_primary_10_5694_mja2_52585
crossref_primary_10_1016_j_drugpo_2021_103458
crossref_primary_10_1186_s12954_019_0298_2
crossref_primary_10_3389_fpubh_2022_877585
crossref_primary_10_1001_jamainternmed_2022_0170
crossref_primary_10_3389_fimmu_2023_1259998
crossref_primary_10_3390_v15081712
crossref_primary_10_1007_s10461_022_03627_3
crossref_primary_10_4000_138ib
crossref_primary_10_1111_add_15316
crossref_primary_10_1007_s11920_019_1038_8
crossref_primary_10_1371_journal_pone_0287333
crossref_primary_10_1007_s10461_018_2149_7
crossref_primary_10_1097_QAD_0000000000001806
crossref_primary_10_1080_01639625_2020_1735024
crossref_primary_10_1007_s10461_021_03312_x
crossref_primary_10_1186_s12954_019_0350_2
crossref_primary_10_1016_j_japh_2022_12_026
crossref_primary_10_3390_v15041027
crossref_primary_10_1186_s12954_025_01171_6
crossref_primary_10_1111_jvh_13496
crossref_primary_10_1016_S2215_0366_22_00435_7
crossref_primary_10_1111_add_16412
crossref_primary_10_1186_s12954_021_00495_3
crossref_primary_10_1186_s12985_019_1157_1
crossref_primary_10_15406_ijfcm_2025_09_00382
crossref_primary_10_1016_j_jsat_2021_108344
crossref_primary_10_1007_s40121_020_00335_0
crossref_primary_10_1016_j_jsat_2021_108587
crossref_primary_10_1093_cid_ciaa142
crossref_primary_10_1186_s13011_020_00306_1
crossref_primary_10_1097_CLD_0000000000000241
crossref_primary_10_1186_s12954_020_00369_0
crossref_primary_10_1111_add_14479
crossref_primary_10_1111_add_70175
crossref_primary_10_1080_09687637_2020_1754764
crossref_primary_10_1111_add_14234
crossref_primary_10_1007_s10620_019_05511_y
crossref_primary_10_1186_s12916_022_02423_z
crossref_primary_10_1371_journal_pmed_1003818
crossref_primary_10_1080_10826084_2022_2026964
crossref_primary_10_3390_life11010017
crossref_primary_10_1016_j_drugpo_2017_12_014
crossref_primary_10_1016_j_drugalcdep_2023_109878
crossref_primary_10_1016_j_jval_2022_12_016
crossref_primary_10_1111_jvh_13023
crossref_primary_10_1080_14659891_2021_1967486
crossref_primary_10_1111_jvh_13020
crossref_primary_10_7759_cureus_67140
crossref_primary_10_1016_j_jsat_2021_108337
crossref_primary_10_1093_ofid_ofy120
crossref_primary_10_5812_hepatmon_99249
crossref_primary_10_1371_journal_pone_0233927
crossref_primary_10_1136_bmjopen_2024_091707
crossref_primary_10_1080_17425255_2020_1814737
crossref_primary_10_1097_MD_0000000000018776
crossref_primary_10_1007_s10461_021_03543_y
crossref_primary_10_1186_s12954_020_00432_w
crossref_primary_10_1016_j_drugpo_2024_104455
crossref_primary_10_1371_journal_pmed_1002973
crossref_primary_10_1371_journal_pone_0252490
crossref_primary_10_1016_j_annepidem_2024_02_004
crossref_primary_10_1111_jvh_13274
crossref_primary_10_1111_add_15301
crossref_primary_10_1111_dar_13828
crossref_primary_10_1371_journal_pone_0216123
crossref_primary_10_1038_s41746_024_01318_y
crossref_primary_10_3390_ijerph192315677
crossref_primary_10_1016_j_drugalcdep_2021_109050
crossref_primary_10_1007_s10461_023_04051_x
crossref_primary_10_1371_journal_pone_0230886
crossref_primary_10_1016_j_jsat_2022_108868
crossref_primary_10_1111_dar_12978
crossref_primary_10_1097_QAD_0000000000002934
crossref_primary_10_1007_s40429_018_0226_7
crossref_primary_10_1016_j_ssmqr_2022_100176
crossref_primary_10_2196_25076
crossref_primary_10_1016_j_drugpo_2023_104145
crossref_primary_10_1111_jvh_13284
crossref_primary_10_1016_j_drugpo_2023_104142
crossref_primary_10_1001_jamanetworkopen_2024_54455
crossref_primary_10_1016_j_drugpo_2023_104192
crossref_primary_10_1016_j_jsat_2021_108553
crossref_primary_10_1111_jdv_17139
crossref_primary_10_1186_s12954_021_00580_7
crossref_primary_10_2217_fvl_2020_0040
crossref_primary_10_1186_s12954_025_01207_x
crossref_primary_10_1016_j_drugpo_2019_01_011
crossref_primary_10_1097_MEG_0000000000001213
crossref_primary_10_1016_j_drugpo_2019_01_012
crossref_primary_10_1080_14787210_2021_1874351
crossref_primary_10_1371_journal_pone_0297584
crossref_primary_10_1093_cid_ciaa105
crossref_primary_10_3390_livers4020013
crossref_primary_10_1016_j_socnet_2024_08_005
crossref_primary_10_1016_j_bbr_2020_112924
crossref_primary_10_1186_s12889_021_10705_z
crossref_primary_10_1016_j_drugpo_2022_103805
crossref_primary_10_1002_hep4_1307
crossref_primary_10_1186_s12874_024_02377_1
crossref_primary_10_1002_hep4_1310
crossref_primary_10_1016_S2352_3018_19_30042_6
crossref_primary_10_1016_j_lanepe_2025_101273
crossref_primary_10_1186_s12879_019_4154_5
crossref_primary_10_1016_j_jsat_2018_08_009
crossref_primary_10_3390_v16010092
crossref_primary_10_1186_s12954_021_00538_9
crossref_primary_10_1016_j_jss_2022_10_004
crossref_primary_10_1016_j_drugpo_2018_04_010
crossref_primary_10_1111_jvh_13480
crossref_primary_10_3390_v13081472
crossref_primary_10_3748_wjg_v27_i16_1728
crossref_primary_10_1093_cid_ciaa571
crossref_primary_10_1186_s12954_020_00358_3
crossref_primary_10_1016_S2352_3018_19_30373_X
crossref_primary_10_1038_s41575_022_00608_8
crossref_primary_10_1097_CEJ_0000000000000553
crossref_primary_10_1016_j_drugalcdep_2021_109003
crossref_primary_10_1093_infdis_jix682
crossref_primary_10_1097_QAD_0000000000002716
crossref_primary_10_1016_j_puhe_2020_06_007
crossref_primary_10_1055_a_2313_0111
crossref_primary_10_1186_s12954_023_00906_7
crossref_primary_10_1016_j_amepre_2021_02_018
crossref_primary_10_1016_j_drugalcdep_2023_110834
crossref_primary_10_1016_j_jsat_2019_11_001
crossref_primary_10_1016_S2352_3018_22_00093_5
crossref_primary_10_1007_s40264_023_01351_y
crossref_primary_10_3389_fpsyt_2022_905314
crossref_primary_10_1111_add_15503
crossref_primary_10_1111_liv_13647
crossref_primary_10_1093_infdis_jiz633
crossref_primary_10_1016_j_drugalcdep_2022_109551
crossref_primary_10_7326_M18_1715
crossref_primary_10_1007_s11096_023_01691_w
crossref_primary_10_1186_s13011_019_0229_y
crossref_primary_10_1186_s12889_024_20646_y
crossref_primary_10_1016_S2468_2667_21_00258_9
crossref_primary_10_1080_1533256X_2019_1659066
crossref_primary_10_1136_bmjopen_2019_036355
crossref_primary_10_1176_appi_ajp_rj_2025_210102
crossref_primary_10_1177_10497315221117543
crossref_primary_10_1371_journal_pone_0301442
crossref_primary_10_1186_s12981_023_00566_4
crossref_primary_10_1016_j_jhep_2020_08_018
crossref_primary_10_3390_pathogens9060432
crossref_primary_10_1186_s12889_025_22357_4
crossref_primary_10_1186_s40249_021_00894_5
crossref_primary_10_1371_journal_pone_0253710
crossref_primary_10_1111_add_15151
crossref_primary_10_1016_j_drugpo_2023_104309
crossref_primary_10_1093_ofid_ofaf339
crossref_primary_10_1016_j_ajog_2020_01_058
crossref_primary_10_1186_s12879_021_06577_8
crossref_primary_10_2105_AJPH_2021_306290
crossref_primary_10_1177_08862605251319017
crossref_primary_10_1038_s41575_024_01003_1
crossref_primary_10_1080_07853890_2022_2028001
crossref_primary_10_1016_j_drugpo_2018_07_001
crossref_primary_10_1016_j_drugpo_2018_07_002
crossref_primary_10_1371_journal_pone_0204795
crossref_primary_10_3390_v17081069
crossref_primary_10_1016_S0140_6736_23_01320_X
crossref_primary_10_1136_bmjopen_2022_065026
crossref_primary_10_1136_sextrans_2024_056150
crossref_primary_10_1016_j_drugpo_2020_102757
crossref_primary_10_1093_cid_ciz726
crossref_primary_10_1080_17441692_2020_1768276
crossref_primary_10_1186_s13011_023_00583_6
crossref_primary_10_1080_09540121_2021_1967853
crossref_primary_10_1111_dar_13407
crossref_primary_10_3390_ijerph21030289
crossref_primary_10_1111_dar_13890
crossref_primary_10_1111_dar_13893
crossref_primary_10_1016_j_jchemneu_2018_12_002
crossref_primary_10_1097_QAD_0000000000002993
crossref_primary_10_1016_j_drugalcdep_2021_108829
crossref_primary_10_1002_jia2_25583
crossref_primary_10_1016_j_jval_2019_06_006
crossref_primary_10_1016_S2215_0366_23_00095_0
crossref_primary_10_1186_s12954_020_00398_9
crossref_primary_10_3390_life13040932
crossref_primary_10_1055_s_0040_1716343
crossref_primary_10_1016_j_drugpo_2024_104616
crossref_primary_10_1080_10530789_2021_1892931
crossref_primary_10_1186_s12889_024_18470_5
crossref_primary_10_1097_QAI_0000000000002743
crossref_primary_10_3389_frph_2024_1438005
crossref_primary_10_1016_j_drugpo_2018_07_016
crossref_primary_10_1016_j_jceh_2025_102501
crossref_primary_10_3390_vaccines10020202
crossref_primary_10_3390_diagnostics11071253
crossref_primary_10_1002_cld_921
crossref_primary_10_1371_journal_pone_0275995
crossref_primary_10_1016_S1473_3099_23_00590_X
crossref_primary_10_1111_dar_13670
crossref_primary_10_1016_j_drugalcdep_2020_107899
crossref_primary_10_4103_jrpp_jrpp_15_25
crossref_primary_10_1038_s41598_019_52564_0
crossref_primary_10_1016_j_drugpo_2018_07_014
crossref_primary_10_1371_journal_pone_0266815
crossref_primary_10_1186_s12879_022_07712_9
crossref_primary_10_1111_add_16203
crossref_primary_10_1007_s40273_024_01424_5
crossref_primary_10_3390_stats7020034
crossref_primary_10_7759_cureus_45716
crossref_primary_10_1371_journal_pone_0231969
crossref_primary_10_1080_14659891_2022_2144503
crossref_primary_10_1111_add_70121
crossref_primary_10_1016_j_drugalcdep_2018_03_048
crossref_primary_10_1186_s12954_023_00841_7
crossref_primary_10_1016_j_josat_2023_208986
crossref_primary_10_1111_add_15111
crossref_primary_10_1016_S0140_6736_19_32320_7
crossref_primary_10_1007_s11481_019_09892_9
crossref_primary_10_1186_s12954_021_00497_1
crossref_primary_10_1080_2156857X_2022_2141839
crossref_primary_10_7759_cureus_65315
crossref_primary_10_1177_0961463X221128736
crossref_primary_10_1136_sextrans_2018_053747
crossref_primary_10_3389_fpubh_2023_1258095
crossref_primary_10_1016_j_drugpo_2023_104124
crossref_primary_10_1097_SGA_0000000000000458
crossref_primary_10_1108_DHS_08_2023_0034
crossref_primary_10_1016_j_jhep_2019_09_022
crossref_primary_10_14309_ajg_0000000000001147
crossref_primary_10_1038_s41575_018_0026_5
crossref_primary_10_1186_s12977_021_00569_x
crossref_primary_10_1016_j_jadohealth_2023_08_046
crossref_primary_10_1016_S2468_1253_20_30303_4
crossref_primary_10_1186_s13011_019_0201_x
crossref_primary_10_1371_journal_pone_0309345
crossref_primary_10_1002_jia2_25577
crossref_primary_10_1136_bmj_m710
crossref_primary_10_3390_v16081277
crossref_primary_10_1186_s12889_020_8178_y
crossref_primary_10_3389_fnut_2024_1387461
crossref_primary_10_1097_QAD_0000000000003651
crossref_primary_10_1186_s12912_019_0347_x
crossref_primary_10_1186_s12954_024_00960_9
crossref_primary_10_1002_jia2_26420
crossref_primary_10_1186_s12954_020_00452_6
crossref_primary_10_4103_ijmr_ijmr_2634_22
crossref_primary_10_1186_s12954_023_00743_8
crossref_primary_10_1111_hiv_13300
crossref_primary_10_1053_j_gastro_2018_10_048
crossref_primary_10_1016_j_ijid_2021_09_041
crossref_primary_10_1016_S1473_3099_18_30469_9
crossref_primary_10_1001_jamanetworkopen_2023_7888
crossref_primary_10_1016_j_drugalcdep_2022_109396
crossref_primary_10_1186_s13011_024_00603_z
crossref_primary_10_1016_j_drugpo_2018_06_019
crossref_primary_10_1002_hep4_1731
crossref_primary_10_1016_j_trsl_2021_03_011
crossref_primary_10_1371_journal_pone_0308482
crossref_primary_10_1016_j_drugpo_2024_104648
crossref_primary_10_1016_j_idc_2020_06_010
crossref_primary_10_1186_s12954_020_00441_9
crossref_primary_10_1186_s13722_022_00325_2
crossref_primary_10_1080_10826084_2023_2177965
crossref_primary_10_1097_ADM_0000000000000910
crossref_primary_10_1007_s10461_022_03932_x
crossref_primary_10_1111_jvh_70065
crossref_primary_10_1016_j_drugpo_2018_09_010
crossref_primary_10_1124_pharmrev_122_000618
crossref_primary_10_1186_s13011_020_00334_x
crossref_primary_10_1007_s10900_023_01218_4
crossref_primary_10_1016_S2468_1253_18_30304_2
crossref_primary_10_1177_1525822X221077398
crossref_primary_10_1002_aid2_13338
crossref_primary_10_1111_hiv_13208
crossref_primary_10_1097_ADM_0000000000000807
crossref_primary_10_1093_cid_ciaa823
crossref_primary_10_1080_09540121_2021_1960945
crossref_primary_10_1186_s12954_023_00746_5
crossref_primary_10_1002_hsr2_151
crossref_primary_10_1111_jrh_12737
crossref_primary_10_1016_S2468_2667_24_00275_5
crossref_primary_10_1007_s15010_024_02433_4
crossref_primary_10_1016_j_drugpo_2022_103696
crossref_primary_10_1016_j_jsat_2019_05_008
crossref_primary_10_1016_S2468_1253_19_30201_8
crossref_primary_10_1093_cid_ciz321
crossref_primary_10_1111_dar_13134
crossref_primary_10_1371_journal_pone_0261500
crossref_primary_10_1016_j_jinf_2022_06_005
crossref_primary_10_3390_microorganisms12122554
crossref_primary_10_1016_S2468_1253_24_00442_4
crossref_primary_10_1093_ofid_ofaf156
crossref_primary_10_1007_s10461_023_04024_0
crossref_primary_10_1016_j_drugpo_2023_103959
crossref_primary_10_1111_jvh_13955
crossref_primary_10_1186_s12889_024_18909_9
crossref_primary_10_1111_jvh_13951
crossref_primary_10_1186_s12889_022_12604_3
crossref_primary_10_1111_dar_13145
crossref_primary_10_3390_ijerph20115937
crossref_primary_10_1177_11782218221095871
crossref_primary_10_1097_QAD_0000000000003570
crossref_primary_10_1111_iwj_13572
crossref_primary_10_1097_JNC_0000000000000016
crossref_primary_10_1111_dar_13389
crossref_primary_10_1136_bmjopen_2020_047350
crossref_primary_10_1007_s10389_024_02276_1
crossref_primary_10_1111_liv_15107
crossref_primary_10_1186_s12954_024_00939_6
crossref_primary_10_1007_s10461_022_03908_x
crossref_primary_10_1016_j_drugpo_2019_04_004
crossref_primary_10_1016_j_bjid_2025_104512
crossref_primary_10_1016_j_drugpo_2019_04_001
crossref_primary_10_1371_journal_pone_0269250
crossref_primary_10_1016_j_ijmmb_2025_100940
crossref_primary_10_1016_j_lanwpc_2023_100801
crossref_primary_10_1016_S2468_1253_18_30270_X
crossref_primary_10_1186_s41124_018_0033_8
crossref_primary_10_1186_s12879_023_08433_3
crossref_primary_10_1177_02537176221127449
crossref_primary_10_1371_journal_pone_0270891
crossref_primary_10_4103_ijsp_ijsp_337_23
crossref_primary_10_1111_add_16283
crossref_primary_10_1111_dar_13798
crossref_primary_10_1016_j_drugpo_2018_08_009
crossref_primary_10_1111_joim_12972
crossref_primary_10_1016_j_drugalcdep_2021_108970
crossref_primary_10_1016_j_jval_2020_03_021
crossref_primary_10_1093_infdis_jiaa130
crossref_primary_10_1186_s12954_020_00385_0
crossref_primary_10_1016_j_drugpo_2021_103387
crossref_primary_10_1371_journal_pone_0216727
crossref_primary_10_1080_14659891_2021_1989509
crossref_primary_10_1177_20503245231199163
crossref_primary_10_1186_s13011_020_00323_0
crossref_primary_10_1097_COH_0000000000000631
crossref_primary_10_1186_s12954_023_00759_0
crossref_primary_10_1186_s12879_020_05541_2
crossref_primary_10_1080_10826084_2021_1914103
crossref_primary_10_1016_j_intimp_2018_10_028
crossref_primary_10_1186_s12954_020_00363_6
crossref_primary_10_1016_j_avsg_2021_06_018
crossref_primary_10_1111_add_16055
crossref_primary_10_1093_infdis_jiz058
crossref_primary_10_1089_tmj_2022_0189
crossref_primary_10_5888_pcd18_200604
crossref_primary_10_1007_s10461_020_03115_6
crossref_primary_10_1080_21645515_2024_2447108
crossref_primary_10_1016_j_drugpo_2021_103398
crossref_primary_10_1093_infdis_jiaa143
crossref_primary_10_1136_bmjopen_2020_039724
crossref_primary_10_7759_cureus_18457
crossref_primary_10_1001_jamanetworkopen_2024_38657
crossref_primary_10_2478_bgbl_2023_0036
crossref_primary_10_1016_j_drugpo_2020_103095
crossref_primary_10_1016_j_drugpo_2021_103394
crossref_primary_10_1016_j_jclinepi_2024_111332
crossref_primary_10_1111_add_16268
crossref_primary_10_1016_S2352_3018_23_00272_2
crossref_primary_10_1111_liv_70191
crossref_primary_10_3390_v14030497
crossref_primary_10_1136_bmjopen_2022_068604
crossref_primary_10_1186_s12879_021_06393_0
crossref_primary_10_1257_app_20210048
crossref_primary_10_1097_EDE_0000000000001110
crossref_primary_10_1177_00333549221074385
crossref_primary_10_3390_ijerph19063269
crossref_primary_10_1097_COH_0000000000000619
crossref_primary_10_3390_ijerph19074158
crossref_primary_10_1016_j_drugalcdep_2020_108436
crossref_primary_10_5812_ijhrba_90078
crossref_primary_10_1080_09540121_2021_1889952
crossref_primary_10_2105_AJPH_2019_305487
crossref_primary_10_1007_s11938_019_00240_7
crossref_primary_10_3390_v14061192
crossref_primary_10_1016_j_drugpo_2019_05_013
crossref_primary_10_1186_s12889_025_22853_7
crossref_primary_10_3389_fmicb_2021_697859
crossref_primary_10_3390_ijerph18126425
crossref_primary_10_1007_s13178_022_00702_1
crossref_primary_10_1007_s13365_023_01186_4
crossref_primary_10_1016_j_ijregi_2023_07_001
crossref_primary_10_15585_mmwr_mm6829a1
crossref_primary_10_1002_jia2_25608
crossref_primary_10_1093_infdis_jiaa129
crossref_primary_10_1093_epirev_mxaa010
crossref_primary_10_21675_2357_707X_2023_v14_e_202316
crossref_primary_10_3390_vaccines12050488
crossref_primary_10_1016_j_drugpo_2018_08_011
crossref_primary_10_1186_s13019_021_01491_1
crossref_primary_10_7189_jogh_14_04077
crossref_primary_10_1111_dar_13595
crossref_primary_10_1016_j_drugpo_2019_05_005
crossref_primary_10_1016_S2352_3018_19_30346_7
crossref_primary_10_1371_journal_pone_0259891
crossref_primary_10_1016_j_drugalcdep_2023_111013
crossref_primary_10_1097_QAD_0000000000003382
crossref_primary_10_3399_BJGPO_2024_0049
crossref_primary_10_1016_j_ajogmf_2021_100418
crossref_primary_10_5009_gnl240451
crossref_primary_10_1016_j_drugalcdep_2018_11_007
crossref_primary_10_1038_s41598_020_63990_w
crossref_primary_10_1093_ofid_ofaa317
crossref_primary_10_1186_s12889_024_18675_8
crossref_primary_10_1016_j_drugpo_2021_103343
crossref_primary_10_1007_s11414_020_09730_4
crossref_primary_10_1136_bmj_n784
crossref_primary_10_1186_s13011_018_0187_9
crossref_primary_10_1186_s13690_021_00623_2
crossref_primary_10_1002_hep_32237
crossref_primary_10_1016_j_drugalcdep_2018_11_010
crossref_primary_10_1016_j_drugalcdep_2024_111384
crossref_primary_10_1016_S0140_6736_19_32229_9
crossref_primary_10_1136_bmjopen_2024_091337
crossref_primary_10_3389_fimmu_2021_663061
crossref_primary_10_1186_s12954_019_0327_1
crossref_primary_10_1016_j_jpsychires_2020_08_013
crossref_primary_10_1007_s44370_024_00002_9
crossref_primary_10_1016_j_biopha_2023_115068
crossref_primary_10_1016_j_jhep_2018_03_026
crossref_primary_10_1186_s12889_020_09068_8
crossref_primary_10_1080_14659891_2020_1846803
crossref_primary_10_1016_j_athoracsur_2020_10_042
crossref_primary_10_1093_cid_ciz162
crossref_primary_10_1093_ofid_ofaa310
crossref_primary_10_1007_s11904_019_00425_w
crossref_primary_10_1111_tme_12935
crossref_primary_10_1016_j_drugpo_2021_103359
crossref_primary_10_1016_j_drugpo_2020_103059
crossref_primary_10_17711_SM_0185_3325_2019_021
crossref_primary_10_1108_IJPH_06_2021_0056
crossref_primary_10_1177_21501319211063999
crossref_primary_10_1016_j_drugpo_2020_103052
crossref_primary_10_1002_hep_32002
crossref_primary_10_1177_21582440231196725
crossref_primary_10_1007_s11524_019_00352_6
crossref_primary_10_1016_j_drugalcdep_2025_112732
crossref_primary_10_1097_QAD_0000000000004263
crossref_primary_10_1186_s12954_023_00737_6
crossref_primary_10_1016_j_drugpo_2019_02_009
crossref_primary_10_1016_j_meegid_2019_104078
crossref_primary_10_1016_j_drugpo_2019_02_007
crossref_primary_10_1111_add_15812
crossref_primary_10_1002_jia2_25817
crossref_primary_10_1080_17441692_2022_2110919
crossref_primary_10_1016_j_drugalcdep_2020_108078
crossref_primary_10_1097_MCG_0000000000001447
crossref_primary_10_1080_00952990_2021_1983821
crossref_primary_10_1016_j_inoche_2023_111269
crossref_primary_10_7759_cureus_9009
crossref_primary_10_7759_cureus_13350
crossref_primary_10_2196_66551
crossref_primary_10_1016_j_drugpo_2021_103127
crossref_primary_10_2471_BLT_18_219469
crossref_primary_10_1016_S2468_1253_23_00018_3
crossref_primary_10_1186_s12954_019_0349_8
crossref_primary_10_1016_j_respe_2022_101421
crossref_primary_10_1093_nsr_nwz207
crossref_primary_10_1371_journal_pone_0266142
crossref_primary_10_1186_s12879_019_4558_2
crossref_primary_10_1186_s40814_023_01311_4
crossref_primary_10_1007_s10461_024_04433_9
crossref_primary_10_1093_cid_ciac140
crossref_primary_10_1097_JS9_0000000000000367
crossref_primary_10_1016_j_drugpo_2021_103134
crossref_primary_10_1186_s12872_025_05034_7
crossref_primary_10_1111_add_14978
crossref_primary_10_1002_kjm2_12086
crossref_primary_10_1016_j_drugpo_2021_103130
crossref_primary_10_1007_s00508_020_01774_y
crossref_primary_10_1016_j_epidem_2019_02_003
crossref_primary_10_1007_s10461_021_03457_9
crossref_primary_10_1177_09564624221111277
crossref_primary_10_1186_s12954_020_00370_7
crossref_primary_10_3390_pathogens12020326
crossref_primary_10_1111_liv_14222
crossref_primary_10_1016_j_drugpo_2019_03_027
crossref_primary_10_1111_jvh_13737
crossref_primary_10_3389_fpubh_2021_735572
crossref_primary_10_1007_s11469_020_00407_9
crossref_primary_10_1016_j_drugpo_2021_103304
crossref_primary_10_1111_add_14944
crossref_primary_10_1111_add_14946
crossref_primary_10_1111_phn_13092
crossref_primary_10_1186_s12954_022_00718_1
crossref_primary_10_1016_S2468_1253_18_30001_3
crossref_primary_10_3389_fmed_2022_814622
crossref_primary_10_1007_s12325_023_02539_5
crossref_primary_10_1186_s12889_025_23204_2
crossref_primary_10_1097_CLD_0000000000000042
crossref_primary_10_1016_j_josat_2024_209449
crossref_primary_10_2196_34555
crossref_primary_10_1111_liv_14232
crossref_primary_10_1186_s12879_019_4218_6
crossref_primary_10_1016_j_drugpo_2022_103654
crossref_primary_10_1080_23744235_2020_1727002
crossref_primary_10_3389_fpsyt_2021_722240
crossref_primary_10_3389_fpsyt_2023_1233844
crossref_primary_10_1080_09687637_2021_1955829
crossref_primary_10_1111_add_15805
crossref_primary_10_1016_j_drugalcdep_2024_112498
crossref_primary_10_1007_s11606_020_06201_6
crossref_primary_10_1016_S2352_3018_21_00274_5
crossref_primary_10_1093_infdis_jiad463
crossref_primary_10_1016_S2468_1253_20_30120_5
crossref_primary_10_1186_s12954_020_00415_x
crossref_primary_10_1002_hsr2_70501
crossref_primary_10_1016_j_ijid_2019_01_015
crossref_primary_10_1016_j_drugpo_2019_03_001
crossref_primary_10_1089_aid_2024_0036
crossref_primary_10_1186_s12954_023_00892_w
crossref_primary_10_1186_s12954_023_00804_y
crossref_primary_10_1016_j_drugalcdep_2021_108560
crossref_primary_10_1016_S2215_0366_20_30538_1
crossref_primary_10_1002_14651858_CD011866_pub3
crossref_primary_10_3390_v14081637
crossref_primary_10_1093_infdis_jiac388
crossref_primary_10_1016_j_drugpo_2020_103036
crossref_primary_10_1016_j_drugpo_2022_103872
crossref_primary_10_1016_j_drugpo_2022_103878
crossref_primary_10_1080_03007995_2020_1775075
crossref_primary_10_1016_j_drugpo_2022_103875
crossref_primary_10_1007_s40121_018_0228_8
crossref_primary_10_1007_s10461_023_04140_x
crossref_primary_10_1080_17441692_2021_2002923
crossref_primary_10_1177_23333936241240795
crossref_primary_10_1016_j_drugpo_2020_103032
crossref_primary_10_1007_s10461_018_2379_8
crossref_primary_10_1007_s40268_023_00443_5
crossref_primary_10_1186_s12954_020_00357_4
crossref_primary_10_1186_s12954_021_00506_3
crossref_primary_10_1080_10826084_2020_1858106
crossref_primary_10_1002_phar_2389
crossref_primary_10_1097_CLD_0000000000000118
crossref_primary_10_1016_j_drugpo_2023_104279
crossref_primary_10_1097_MD_0000000000019963
crossref_primary_10_1111_jvh_13376
crossref_primary_10_1016_j_jacadv_2025_101900
crossref_primary_10_1186_s12916_019_1411_9
crossref_primary_10_1016_j_drugpo_2023_104281
crossref_primary_10_1186_s12954_019_0286_6
crossref_primary_10_1097_CXA_0000000000000208
crossref_primary_10_3390_jcm11051183
crossref_primary_10_3390_pathogens10070835
crossref_primary_10_1186_s12954_023_00829_3
crossref_primary_10_1371_journal_pone_0287683
crossref_primary_10_1080_10826084_2023_2294966
crossref_primary_10_1093_ofid_ofab489
crossref_primary_10_4103_jfsm_jfsm_55_21
crossref_primary_10_1016_j_drugpo_2024_104545
crossref_primary_10_1016_j_drugpo_2019_07_016
crossref_primary_10_1016_j_jsat_2021_108459
crossref_primary_10_1093_ofid_ofy001
crossref_primary_10_1097_TXD_0000000000001211
crossref_primary_10_4274_vhd_galenos_2022_2021_2_3
crossref_primary_10_1111_add_14567
crossref_primary_10_1016_j_ijid_2019_06_003
crossref_primary_10_1016_S2468_2667_21_00248_6
crossref_primary_10_5435_JAAOS_D_21_00651
crossref_primary_10_1093_ofid_ofab474
crossref_primary_10_3390_jcm10174001
crossref_primary_10_1016_j_jvs_2020_05_074
crossref_primary_10_1016_j_drugpo_2021_103401
crossref_primary_10_3390_v13122387
crossref_primary_10_1016_j_drugpo_2024_104576
crossref_primary_10_1093_ofid_ofaa380
crossref_primary_10_3390_jcm13051398
crossref_primary_10_1186_s40352_018_0081_6
crossref_primary_10_1186_s13011_017_0140_3
crossref_primary_10_3390_ijerph182111158
crossref_primary_10_1016_j_drugpo_2024_104570
crossref_primary_10_1016_S0140_6736_18_31469_7
crossref_primary_10_1186_s12954_024_01068_w
crossref_primary_10_1016_j_apnu_2024_07_007
crossref_primary_10_1093_cid_ciaa246
crossref_primary_10_3748_wjg_v26_i30_4415
crossref_primary_10_1186_s13011_020_00286_2
crossref_primary_10_1016_S2468_1253_23_00321_7
crossref_primary_10_1016_j_jsat_2021_108684
crossref_primary_10_1016_j_drugalcdep_2021_109177
crossref_primary_10_1016_j_jhsa_2021_05_016
crossref_primary_10_1093_ofid_ofab457
crossref_primary_10_1093_ofid_ofaa377
crossref_primary_10_1177_10497323231173788
crossref_primary_10_1016_j_drugpo_2025_104868
crossref_primary_10_1016_j_drugpo_2024_104326
crossref_primary_10_1016_j_josat_2024_209431
crossref_primary_10_1016_j_drugpo_2019_07_030
crossref_primary_10_1080_14659891_2020_1736666
crossref_primary_10_3390_ijerph17030800
crossref_primary_10_1016_j_drugpo_2019_07_038
crossref_primary_10_1093_cid_ciaa1346
crossref_primary_10_3389_fmed_2021_774793
crossref_primary_10_1111_add_15630
crossref_primary_10_1177_02537176221086013
crossref_primary_10_1371_journal_pone_0223829
crossref_primary_10_1111_add_15636
crossref_primary_10_1016_j_apnu_2021_09_001
crossref_primary_10_1017_S1368980020004309
crossref_primary_10_1016_S0140_6736_19_32230_5
crossref_primary_10_1186_s13063_023_07074_w
crossref_primary_10_1016_S0140_6736_18_32277_3
crossref_primary_10_1080_10550887_2020_1771235
crossref_primary_10_1016_j_jfma_2020_04_002
crossref_primary_10_1016_j_socscimed_2021_113809
crossref_primary_10_1111_jvh_13575
crossref_primary_10_1016_j_drugpo_2023_104073
crossref_primary_10_1007_s10461_025_04645_7
crossref_primary_10_1016_S2352_3018_18_30168_1
crossref_primary_10_1097_JCMA_0000000000000312
crossref_primary_10_3390_vaccines13060612
crossref_primary_10_1128_spectrum_01447_22
crossref_primary_10_1016_S2468_2667_24_00126_9
crossref_primary_10_1186_s12954_022_00689_3
crossref_primary_10_1016_j_drugpo_2019_06_016
crossref_primary_10_1097_ADM_0000000000001265
crossref_primary_10_1016_j_drugpo_2019_102608
crossref_primary_10_1128_JVI_01657_20
crossref_primary_10_1080_01459740_2022_2110090
crossref_primary_10_1093_eurpub_ckad008
crossref_primary_10_1111_acem_13559
crossref_primary_10_1186_s12954_020_00424_w
crossref_primary_10_1136_bcr_2020_239376
crossref_primary_10_3390_jcm10214955
crossref_primary_10_1016_j_drugpo_2025_104883
crossref_primary_10_1016_j_trsl_2020_03_012
crossref_primary_10_1111_jvh_13586
crossref_primary_10_1016_j_intimp_2022_108696
crossref_primary_10_1093_cid_ciab546
crossref_primary_10_1001_jamanetworkopen_2022_0541
crossref_primary_10_1016_j_drugalcdep_2021_109121
crossref_primary_10_1136_heartjnl_2020_317034
crossref_primary_10_1016_j_cjca_2022_06_004
crossref_primary_10_2196_56958
crossref_primary_10_1016_j_drugpo_2022_103917
crossref_primary_10_1016_j_drugalcdep_2022_109686
crossref_primary_10_1186_s12879_021_06817_x
crossref_primary_10_1080_00952990_2021_2024559
crossref_primary_10_1016_j_jacc_2022_03_349
crossref_primary_10_1186_s12879_018_3439_4
crossref_primary_10_1186_s13722_024_00505_2
crossref_primary_10_1007_s00705_019_04285_y
crossref_primary_10_1016_j_drugpo_2025_104894
crossref_primary_10_1016_j_drugalcdep_2020_107906
crossref_primary_10_1002_jia2_25054
crossref_primary_10_1089_apc_2020_0077
crossref_primary_10_1093_ofid_ofac350
crossref_primary_10_1016_j_cld_2021_06_008
crossref_primary_10_1016_j_drugpo_2022_103906
crossref_primary_10_1001_jamanetworkopen_2025_11641
crossref_primary_10_1097_JOM_0000000000001754
crossref_primary_10_1016_j_drugpo_2022_103910
crossref_primary_10_1097_QAD_0000000000002611
crossref_primary_10_1002_cnma_202400032
crossref_primary_10_1002_jia2_25287
crossref_primary_10_1080_10509674_2023_2286655
crossref_primary_10_1186_s13063_021_05079_x
crossref_primary_10_3389_fpubh_2023_1041201
crossref_primary_10_3390_medicina58030436
crossref_primary_10_1371_journal_pone_0305923
crossref_primary_10_1093_ofid_ofaf454
crossref_primary_10_1093_ofid_ofaf211
crossref_primary_10_1111_add_16365
crossref_primary_10_1136_bmjopen_2020_041629
crossref_primary_10_3390_ijerph16193749
crossref_primary_10_1016_j_abrep_2021_100398
crossref_primary_10_1016_j_dadr_2023_100204
crossref_primary_10_1007_s10461_023_04113_0
crossref_primary_10_1371_journal_pone_0330210
crossref_primary_10_5604_01_3001_0010_7529
crossref_primary_10_1093_ofid_ofae350
crossref_primary_10_3390_ijerph192315732
crossref_primary_10_1016_j_drugalcdep_2019_107793
crossref_primary_10_1186_s12981_023_00578_0
crossref_primary_10_1016_S2468_1253_19_30085_8
crossref_primary_10_1371_journal_pone_0215570
crossref_primary_10_1016_j_drugpo_2020_102877
crossref_primary_10_1111_dar_13525
crossref_primary_10_1007_s10729_022_09607_2
crossref_primary_10_1097_QAD_0000000000003718
crossref_primary_10_1111_add_15045
crossref_primary_10_1016_S2215_0366_22_00318_2
crossref_primary_10_1002_jia2_25468
crossref_primary_10_1016_j_drugalcdep_2021_108702
crossref_primary_10_1016_S2468_2667_21_00013_X
crossref_primary_10_1111_dar_13772
crossref_primary_10_1002_jia2_25222
crossref_primary_10_1371_journal_pone_0323919
crossref_primary_10_1097_OLQ_0000000000001214
crossref_primary_10_1177_1367493519831499
crossref_primary_10_1007_s10461_023_04213_x
crossref_primary_10_1186_s12954_024_01037_3
crossref_primary_10_1007_s11904_020_00498_y
crossref_primary_10_1016_S2468_1253_17_30404_1
crossref_primary_10_1016_j_mcna_2021_08_007
crossref_primary_10_1016_j_ypmed_2020_106040
crossref_primary_10_1002_jia2_70023
crossref_primary_10_1016_S2468_1253_18_30307_8
crossref_primary_10_1016_j_drugpo_2019_102619
crossref_primary_10_1016_j_drugpo_2019_102613
crossref_primary_10_1136_bmjopen_2020_040556
crossref_primary_10_1016_j_emc_2024_02_004
crossref_primary_10_1093_ofid_ofac150
crossref_primary_10_1016_j_aohep_2020_02_003
crossref_primary_10_1002_jmv_25415
crossref_primary_10_1186_s12954_020_00409_9
crossref_primary_10_1097_JAN_0000000000000402
crossref_primary_10_1186_s12879_019_3832_7
crossref_primary_10_1016_j_drugpo_2020_102663
crossref_primary_10_1016_j_lanwpc_2022_100468
crossref_primary_10_1186_s12954_025_01185_0
crossref_primary_10_1007_s13337_022_00797_5
crossref_primary_10_1111_add_14383
crossref_primary_10_1093_cid_ciz633
crossref_primary_10_1093_ofid_ofaf257
crossref_primary_10_1007_s10461_021_03495_3
crossref_primary_10_1186_s12888_022_03814_5
crossref_primary_10_1093_cid_ciaf082
crossref_primary_10_1016_j_drugpo_2023_104237
crossref_primary_10_1186_s12889_025_21724_5
crossref_primary_10_1111_liv_13949
crossref_primary_10_1111_add_14393
crossref_primary_10_1016_j_socscimed_2020_113352
crossref_primary_10_1007_s40271_020_00489_6
crossref_primary_10_3390_v16071115
crossref_primary_10_1177_0974150X221127450
crossref_primary_10_1186_s13011_021_00368_9
crossref_primary_10_1016_j_drugpo_2020_102832
crossref_primary_10_1002_hep4_1826
crossref_primary_10_1093_eurpub_ckz064
crossref_primary_10_1016_j_drugpo_2020_102837
crossref_primary_10_1016_S2468_1253_20_30359_9
crossref_primary_10_1016_j_drugpo_2025_104803
crossref_primary_10_1371_journal_pone_0258267
crossref_primary_10_1093_cid_ciaa612
crossref_primary_10_1111_jvh_13187
crossref_primary_10_3390_ijerph17155483
crossref_primary_10_1186_s12954_019_0299_1
crossref_primary_10_1371_journal_pone_0218852
crossref_primary_10_1111_add_15456
crossref_primary_10_1111_add_16305
crossref_primary_10_3389_fimmu_2021_734871
crossref_primary_10_3389_fpubh_2022_952909
crossref_primary_10_1016_j_mmifmc_2022_09_007
crossref_primary_10_1002_hec_3944
crossref_primary_10_1186_s12954_021_00485_5
crossref_primary_10_1016_j_drugpo_2020_102866
crossref_primary_10_1111_dar_12883
crossref_primary_10_1186_s12954_021_00561_w
crossref_primary_10_3390_ijerph22030340
crossref_primary_10_1016_j_eclinm_2024_103040
crossref_primary_10_1186_s12954_022_00649_x
crossref_primary_10_3390_biology11060805
crossref_primary_10_1007_s00508_020_01790_y
crossref_primary_10_1016_j_drugalcdep_2020_107983
crossref_primary_10_1007_s10900_023_01278_6
crossref_primary_10_2196_47395
crossref_primary_10_1016_j_drugpo_2020_102875
crossref_primary_10_1016_j_jhep_2023_12_020
crossref_primary_10_3389_fcvm_2022_1007118
crossref_primary_10_2147_HIV_S366970
crossref_primary_10_1016_j_drugpo_2019_102656
crossref_primary_10_3390_pathogens10121619
crossref_primary_10_1093_cid_ciaa607
crossref_primary_10_1186_s12954_024_00983_2
crossref_primary_10_1016_j_puhe_2023_09_024
crossref_primary_10_1155_2024_3184892
crossref_primary_10_1001_jamanetworkopen_2019_3613
crossref_primary_10_1016_j_avsg_2020_06_017
crossref_primary_10_2147_TCRM_S409134
crossref_primary_10_1093_ofid_ofaf226
crossref_primary_10_7554_eLife_81070
crossref_primary_10_1016_j_drugpo_2020_102862
crossref_primary_10_1093_cid_ciz661
crossref_primary_10_1097_QAD_0000000000002455
crossref_primary_10_1186_s12954_023_00766_1
crossref_primary_10_1371_journal_pone_0295670
crossref_primary_10_1186_s12954_021_00519_y
crossref_primary_10_1007_s11904_018_0406_z
crossref_primary_10_1001_jamanetworkopen_2024_37861
crossref_primary_10_1080_10826084_2022_2125273
Cites_doi 10.7326/0003-4819-151-4-200908180-00135
10.1081/ADA-100101843
10.1186/1747-597X-7-9
10.1016/S0140-6736(11)61097-0
10.1111/add.12938
10.1111/add.13491
10.1016/S0140-6736(16)30388-9
10.1093/eurpub/ckq076
10.1097/QAI.0000000000000637
10.1016/S0140-6736(10)60742-8
10.1016/j.drugpo.2016.12.010
10.1016/S0376-8716(99)00102-7
10.1097/01.aids.0000218555.36661.9c
10.1016/S0140-6736(16)30856-X
10.1016/S1473-3099(16)30325-5
10.1002/hep.26387
10.1016/S0140-6736(08)61311-2
10.1097/OLQ.0000000000000504
10.1016/S0140-6736(16)30379-8
10.1016/S0140-6736(16)30769-3
10.1093/aje/kwu056
10.1001/archinte.167.2.166
10.1371/journal.pone.0177341
10.1093/cid/civ197
10.1016/S2214-109X(17)30373-X
ContentType Journal Article
Copyright 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.
2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license 2017
Copyright_xml – notice: 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license
– notice: Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.
– notice: 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license 2017
DBID 6I.
AAFTH
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.1016/S2214-109X(17)30375-3
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList


MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals (DOAJ)
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Public Health
EISSN 2214-109X
EndPage e1207
ExternalDocumentID oai_doaj_org_article_a8463239558a4e58a3933c2d2c439467
PMC5683738
29074409
10_1016_S2214_109X_17_30375_3
S2214109X17303753
Genre Systematic Review
Journal Article
GrantInformation Australian National Drug and Alcohol Research Centre, Australian National Health and Medical Research Council, Open Society Foundation, World Health Organization, the Global Fund, and UNAIDS.
GrantInformation_xml – fundername: Medical Research Council
  grantid: G1000021
– fundername: NIDA NIH HHS
  grantid: R01 DA037773
– fundername: Medical Research Council
  grantid: MR/K023233/1
GroupedDBID .1-
.FO
0R~
1P~
457
53G
AAEDT
AAEDW
AAIKJ
AALRI
AAMRU
AAXUO
AAYWO
ABMAC
ACGFS
ACHQT
ACVFH
ADBBV
ADCNI
ADEZE
ADVLN
AENEX
AEUPX
AEVXI
AEXQZ
AFPUW
AFRHN
AFTJW
AGHFR
AIGII
AITUG
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
APXCP
BAWUL
BCNDV
DIK
EBS
EJD
FDB
GROUPED_DOAJ
HZ~
IPNFZ
IXB
KQ8
M41
M~E
O9-
OD.
OK1
OO~
RIG
ROL
SSZ
Z5R
0SF
6I.
AACTN
AAFTH
AFCTW
NCXOZ
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ID FETCH-LOGICAL-c653t-b3160211ce147f36e36f99bcbc87a277e70fc7aae13e826faefaeb4bed785f963
IEDL.DBID DOA
ISICitedReferencesCount 1130
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000414869500020&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2214-109X
IngestDate Fri Oct 03 12:38:47 EDT 2025
Thu Aug 21 13:23:45 EDT 2025
Fri Sep 05 12:04:00 EDT 2025
Tue Jun 24 01:32:01 EDT 2025
Wed Nov 05 20:46:15 EST 2025
Tue Nov 18 21:47:39 EST 2025
Wed May 17 01:33:42 EDT 2023
Tue Aug 26 16:32:27 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 12
Language English
License This is an open access article under the CC BY-NC-ND license.
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c653t-b3160211ce147f36e36f99bcbc87a277e70fc7aae13e826faefaeb4bed785f963
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ObjectType-Undefined-4
Joint senior authors
OpenAccessLink https://doaj.org/article/a8463239558a4e58a3933c2d2c439467
PMID 29074409
PQID 1957468702
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_a8463239558a4e58a3933c2d2c439467
pubmedcentral_primary_oai_pubmedcentral_nih_gov_5683738
proquest_miscellaneous_1957468702
pubmed_primary_29074409
crossref_primary_10_1016_S2214_109X_17_30375_3
crossref_citationtrail_10_1016_S2214_109X_17_30375_3
elsevier_sciencedirect_doi_10_1016_S2214_109X_17_30375_3
elsevier_clinicalkey_doi_10_1016_S2214_109X_17_30375_3
PublicationCentury 2000
PublicationDate 2017-12-01
PublicationDateYYYYMMDD 2017-12-01
PublicationDate_xml – month: 12
  year: 2017
  text: 2017-12-01
  day: 01
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle The Lancet global health
PublicationTitleAlternate Lancet Glob Health
PublicationYear 2017
Publisher Elsevier Ltd
Elsevier
Publisher_xml – name: Elsevier Ltd
– name: Elsevier
References Fraser H, Martin NK, Brummer-Korvenkontio H, et al. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe.
Medhi, Mahanta, Akoijam, Adhikary (bib33) 2012; 7
Hickman, Taylor, Chatterjee (bib29) 2002; LIV
Banerjee, Edelman, Barry (bib37) 2016; 111
(bib5) 2005
Kozlov, Shaboltas, Toussova (bib20) 2006; 20
Altice, Azbel, Stone (bib4) 2016; 388
Degenhardt, Mathers, Vickerman, Rhodes, Latkin, Hickman (bib3) 2010; 376
bib12
Moher, Liberati, Tetzlaff, Altman (bib23) 2009; 151
Rich, Beckwith, Macmadu (bib42) 2016; 388
(bib40) 2016
(bib2) 2011
Kaye, Darke (bib22) 2000; 58
Mathers, Degenhardt, Phillips (bib6) 2008; 372
Springer, Larney, Alam-Mehrjerdi, Altice, Metzger, Shoptaw (bib19) 2015; 69
(bib10) 2017
Larney (bib27) 2017
Degenhardt, Charlson, Stanaway (bib1) 2016; 16
(bib28) 2016
Jones, Hickman, Welton, De Angelis, Harris, Ades (bib30) 2014; 179
Armstrong (bib35) 2007; 167
Barratt, Hunt, Stoicescu (bib18) 2013
Larney, Kopinski, Beckwith (bib15) 2013; 58
(bib38) 2001
(in press).
Wood, Werb, Beletsky (bib14) 2017; 41
Eckhardt, Winkelstein, Shu (bib13) 2017; 12
Genberg, Astemborski, Vlahov, Kirk, Mehta (bib16) 2015; 110
(bib26) 2016
Degenhardt, Gibson, Leung, Kumvaj, Larney (bib25) 2016
Stevens, Alkema, Black (bib24) 2016; 388
Nelson, Mathers, Cowie (bib7) 2011; 378
(bib9) 2016
Dore, Feld (bib39) 2015; 60
Blouin, Leclerc, Morissette (bib17) 2016; 43
Zule, Desmond (bib21) 1999; 25
(bib36) 2011
(bib11) 2014
(bib41) 2014
Kamarulzaman, Reid, Schwitters (bib43) 2016; 388
(bib34) 2010
Ball, Rana, Dehne (bib8) 1998; 113
Barrio Anta, Oliva, Bravo, De Mateo, Domingo-Salvany (bib31) 2011; 21
Genberg (10.1016/S2214-109X(17)30375-3_bib16) 2015; 110
(10.1016/S2214-109X(17)30375-3_bib2) 2011
(10.1016/S2214-109X(17)30375-3_bib9) 2016
10.1016/S2214-109X(17)30375-3_bib32
(10.1016/S2214-109X(17)30375-3_bib40) 2016
Kozlov (10.1016/S2214-109X(17)30375-3_bib20) 2006; 20
Stevens (10.1016/S2214-109X(17)30375-3_bib24) 2016; 388
Wood (10.1016/S2214-109X(17)30375-3_bib14) 2017; 41
Springer (10.1016/S2214-109X(17)30375-3_bib19) 2015; 69
Banerjee (10.1016/S2214-109X(17)30375-3_bib37) 2016; 111
Moher (10.1016/S2214-109X(17)30375-3_bib23) 2009; 151
(10.1016/S2214-109X(17)30375-3_bib41) 2014
Degenhardt (10.1016/S2214-109X(17)30375-3_bib3) 2010; 376
(10.1016/S2214-109X(17)30375-3_bib5) 2005
Ball (10.1016/S2214-109X(17)30375-3_bib8) 1998; 113
Degenhardt (10.1016/S2214-109X(17)30375-3_bib25) 2016
Jones (10.1016/S2214-109X(17)30375-3_bib30) 2014; 179
Mathers (10.1016/S2214-109X(17)30375-3_bib6) 2008; 372
Kamarulzaman (10.1016/S2214-109X(17)30375-3_bib43) 2016; 388
(10.1016/S2214-109X(17)30375-3_bib36) 2011
Hickman (10.1016/S2214-109X(17)30375-3_bib29) 2002; LIV
(10.1016/S2214-109X(17)30375-3_bib26) 2016
Barratt (10.1016/S2214-109X(17)30375-3_bib18) 2013
Rich (10.1016/S2214-109X(17)30375-3_bib42) 2016; 388
(10.1016/S2214-109X(17)30375-3_bib34) 2010
Degenhardt (10.1016/S2214-109X(17)30375-3_bib1) 2016; 16
Altice (10.1016/S2214-109X(17)30375-3_bib4) 2016; 388
(10.1016/S2214-109X(17)30375-3_bib11) 2014
(10.1016/S2214-109X(17)30375-3_bib28) 2016
Armstrong (10.1016/S2214-109X(17)30375-3_bib35) 2007; 167
Kaye (10.1016/S2214-109X(17)30375-3_bib22) 2000; 58
Blouin (10.1016/S2214-109X(17)30375-3_bib17) 2016; 43
(10.1016/S2214-109X(17)30375-3_bib38) 2001
Nelson (10.1016/S2214-109X(17)30375-3_bib7) 2011; 378
Larney (10.1016/S2214-109X(17)30375-3_bib15) 2013; 58
Medhi (10.1016/S2214-109X(17)30375-3_bib33) 2012; 7
Dore (10.1016/S2214-109X(17)30375-3_bib39) 2015; 60
Barrio Anta (10.1016/S2214-109X(17)30375-3_bib31) 2011; 21
Eckhardt (10.1016/S2214-109X(17)30375-3_bib13) 2017; 12
Zule (10.1016/S2214-109X(17)30375-3_bib21) 1999; 25
Larney (10.1016/S2214-109X(17)30375-3_bib27) 2017
29153723 - Lancet Glob Health. 2018 Jan;6(1):e36. doi: 10.1016/S2214-109X(17)30446-1.
29132603 - Lancet Glob Health. 2017 Dec;5(12):e1162-e1163. doi: 10.1016/S2214-109X(17)30430-8.
References_xml – volume: 378
  start-page: 571
  year: 2011
  end-page: 583
  ident: bib7
  article-title: Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews
  publication-title: Lancet
– volume: 113
  start-page: 170
  year: 1998
  end-page: 181
  ident: bib8
  article-title: HIV prevention among injecting drug users: responses in developing and transitional countries
  publication-title: Public Health Rep
– volume: 388
  start-page: e19
  year: 2016
  end-page: e23
  ident: bib24
  article-title: Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement
  publication-title: Lancet
– ident: bib12
  article-title: A/RES/70/1: transforming our world: the 2030 agenda for sustainable development. Resolution of the United Nations General Assembly Paper on September 25th 2015
– year: 2016
  ident: bib9
  publication-title: World Drug Report 2016
– year: 2010
  ident: bib34
  publication-title: Treatment and care for older drug users
– volume: 43
  start-page: 648
  year: 2016
  end-page: 655
  ident: bib17
  article-title: Sex work as an emerging risk factor for human immunodeficiency virus seroconversion among people who inject drugs in the SurvUDI Network
  publication-title: Sex Transm Dis
– volume: LIV
  start-page: 15
  year: 2002
  end-page: 32
  ident: bib29
  article-title: Estimating the prevalence of problematic drug use: a review of methods and their application
  publication-title: Bull Narc
– volume: 388
  start-page: 1228
  year: 2016
  end-page: 1248
  ident: bib4
  article-title: The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia
  publication-title: Lancet
– volume: 60
  start-page: 1829
  year: 2015
  end-page: 1836
  ident: bib39
  article-title: Hepatitis C virus therapeutic development: in pursuit of “perfectovir”
  publication-title: Clin Infect Dis
– year: 2017
  ident: bib27
  article-title: A systematic review to estimate global, regional and national coverage of HIV prevention and treatment services for people who inject drugs
  publication-title: Lancet Glob Health
– year: 2011
  ident: bib2
  publication-title: Prevention and control of infectious diseases among people who inject drugs
– year: 2014
  ident: bib41
  publication-title: Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations
– volume: 388
  start-page: 1103
  year: 2016
  end-page: 1114
  ident: bib42
  article-title: Clinical care of incarcerated people with HIV, viral hepatitis, or tuberculosis
  publication-title: Lancet
– year: 2016
  ident: bib40
  publication-title: A/RES/S-30/1. Our joint commitment to effectively addressing and countering the world drug problem. Resolution adopted by the General Assembly on 19 April 2016
– volume: 41
  start-page: 132
  year: 2017
  end-page: 139
  ident: bib14
  article-title: Differential experiences of Mexican policing by people who inject drugs residing in Tijuana and San Diego
  publication-title: Int J Drug Policy
– year: 2016
  ident: bib25
  publication-title: Searching the grey literature to access research on illicit drug use, HIV and viral hepatitis: a resource to identify drug-related databases and websites. NDARC Technical Report No. 334
– volume: 16
  start-page: 1385
  year: 2016
  end-page: 1398
  ident: bib1
  article-title: Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013
  publication-title: Lancet Infect Dis
– volume: 69
  start-page: S155
  year: 2015
  end-page: S161
  ident: bib19
  article-title: Drug treatment as HIV prevention among women and girls who inject drugs from a global perspective: progress, gaps, and future directions
  publication-title: J Acquir Immune Defic Syndr
– year: 2014
  ident: bib11
  publication-title: 90–90–90 An ambitious treatment target to help end the AIDS epidemic
– volume: 12
  start-page: e0177341
  year: 2017
  ident: bib13
  article-title: Risk factors for hepatitis C seropositivity among young people who inject drugs in New York City: implications for prevention
  publication-title: PLoS One
– year: 2013
  ident: bib18
  publication-title: Injecting drug use among under-18s: a snapshot of available data
– volume: 25
  start-page: 1
  year: 1999
  end-page: 23
  ident: bib21
  article-title: An ethnographic comparison of HIV risk behaviors among heroin and methamphetamine injectors
  publication-title: Am J Drug Alcohol Abuse
– volume: 111
  start-page: 2021
  year: 2016
  end-page: 2031
  ident: bib37
  article-title: Non-medical use of prescription opioids is associated with heroin initiation among US veterans: a prospective cohort study
  publication-title: Addiction
– year: 2016
  ident: bib28
  publication-title: World population prospects: the 2015 revision
– volume: 110
  start-page: 1152
  year: 2015
  end-page: 1159
  ident: bib16
  article-title: Incarceration and injection drug use in Baltimore, Maryland
  publication-title: Addiction
– volume: 167
  start-page: 166
  year: 2007
  end-page: 173
  ident: bib35
  article-title: Injection drug users in the united states, 1979–2002: an aging population
  publication-title: Arch Intern Med
– volume: 151
  start-page: 264
  year: 2009
  ident: bib23
  article-title: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
  publication-title: Ann Intern Med
– volume: 376
  start-page: 285
  year: 2010
  end-page: 301
  ident: bib3
  article-title: Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed
  publication-title: Lancet
– year: 2016
  ident: bib26
  publication-title: The Global State of Harm Reduction
– year: 2001
  ident: bib38
  publication-title: Declaration of Commitment on HIV/AIDS. UN General Assembly Special session on HIV/AIDS. 2 August 2001
– volume: 179
  start-page: 1383
  year: 2014
  end-page: 1393
  ident: bib30
  article-title: Recapture or precapture? Fallibility of standard capture-recapture methods in the presence of referrals between sources
  publication-title: Am J Epidemiol
– year: 2005
  ident: bib5
  publication-title: Guidelines for viral hepatitis surveillance and case management
– year: 2011
  ident: bib36
  publication-title: ‘Double jeopardy’: older injecting opioid users in Australia—AIVL Discussion Paper
– year: 2017
  ident: bib10
  article-title: Global health sector strategy on viral hepatitis 2016–2021
– volume: 21
  start-page: 646
  year: 2011
  end-page: 648
  ident: bib31
  article-title: Estimating the prevalence of drug injection using a multiplier method based on a register of new HIV diagnoses
  publication-title: Eur J Public Health
– volume: 58
  start-page: 1215
  year: 2013
  end-page: 1224
  ident: bib15
  article-title: The incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis
  publication-title: Hepatology
– volume: 58
  start-page: 189
  year: 2000
  end-page: 195
  ident: bib22
  article-title: A comparison of the harms associated with the injection of heroin and amphetamines
  publication-title: Drug Alcohol Depend
– volume: 372
  start-page: 1733
  year: 2008
  end-page: 1745
  ident: bib6
  article-title: Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review
  publication-title: Lancet
– volume: 20
  start-page: 901
  year: 2006
  end-page: 906
  ident: bib20
  article-title: HIV incidence and factors associated with HIV acquisition among injection drug users in St Petersburg, Russia
  publication-title: AIDS
– volume: 388
  start-page: 1115
  year: 2016
  end-page: 1126
  ident: bib43
  article-title: Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners
  publication-title: Lancet
– reference: (in press).
– volume: 7
  start-page: 9
  year: 2012
  ident: bib33
  article-title: Size estimation of injecting drug users (IDU) using multiplier method in five districts of India
  publication-title: Subst Abuse Treat Prev Policy
– reference: Fraser H, Martin NK, Brummer-Korvenkontio H, et al. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe.
– volume: 151
  start-page: 264
  year: 2009
  ident: 10.1016/S2214-109X(17)30375-3_bib23
  article-title: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
  publication-title: Ann Intern Med
  doi: 10.7326/0003-4819-151-4-200908180-00135
– year: 2013
  ident: 10.1016/S2214-109X(17)30375-3_bib18
– volume: 25
  start-page: 1
  year: 1999
  ident: 10.1016/S2214-109X(17)30375-3_bib21
  article-title: An ethnographic comparison of HIV risk behaviors among heroin and methamphetamine injectors
  publication-title: Am J Drug Alcohol Abuse
  doi: 10.1081/ADA-100101843
– volume: 7
  start-page: 9
  year: 2012
  ident: 10.1016/S2214-109X(17)30375-3_bib33
  article-title: Size estimation of injecting drug users (IDU) using multiplier method in five districts of India
  publication-title: Subst Abuse Treat Prev Policy
  doi: 10.1186/1747-597X-7-9
– year: 2011
  ident: 10.1016/S2214-109X(17)30375-3_bib2
– volume: 378
  start-page: 571
  year: 2011
  ident: 10.1016/S2214-109X(17)30375-3_bib7
  article-title: Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews
  publication-title: Lancet
  doi: 10.1016/S0140-6736(11)61097-0
– volume: 110
  start-page: 1152
  year: 2015
  ident: 10.1016/S2214-109X(17)30375-3_bib16
  article-title: Incarceration and injection drug use in Baltimore, Maryland
  publication-title: Addiction
  doi: 10.1111/add.12938
– volume: 111
  start-page: 2021
  year: 2016
  ident: 10.1016/S2214-109X(17)30375-3_bib37
  article-title: Non-medical use of prescription opioids is associated with heroin initiation among US veterans: a prospective cohort study
  publication-title: Addiction
  doi: 10.1111/add.13491
– volume: 113
  start-page: 170
  issue: suppl 1
  year: 1998
  ident: 10.1016/S2214-109X(17)30375-3_bib8
  article-title: HIV prevention among injecting drug users: responses in developing and transitional countries
  publication-title: Public Health Rep
– volume: 388
  start-page: e19
  year: 2016
  ident: 10.1016/S2214-109X(17)30375-3_bib24
  article-title: Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement
  publication-title: Lancet
  doi: 10.1016/S0140-6736(16)30388-9
– volume: 21
  start-page: 646
  year: 2011
  ident: 10.1016/S2214-109X(17)30375-3_bib31
  article-title: Estimating the prevalence of drug injection using a multiplier method based on a register of new HIV diagnoses
  publication-title: Eur J Public Health
  doi: 10.1093/eurpub/ckq076
– volume: 69
  start-page: S155
  issue: suppl 2
  year: 2015
  ident: 10.1016/S2214-109X(17)30375-3_bib19
  article-title: Drug treatment as HIV prevention among women and girls who inject drugs from a global perspective: progress, gaps, and future directions
  publication-title: J Acquir Immune Defic Syndr
  doi: 10.1097/QAI.0000000000000637
– year: 2016
  ident: 10.1016/S2214-109X(17)30375-3_bib26
– year: 2011
  ident: 10.1016/S2214-109X(17)30375-3_bib36
– volume: 376
  start-page: 285
  year: 2010
  ident: 10.1016/S2214-109X(17)30375-3_bib3
  article-title: Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed
  publication-title: Lancet
  doi: 10.1016/S0140-6736(10)60742-8
– year: 2016
  ident: 10.1016/S2214-109X(17)30375-3_bib25
– year: 2010
  ident: 10.1016/S2214-109X(17)30375-3_bib34
– volume: 41
  start-page: 132
  year: 2017
  ident: 10.1016/S2214-109X(17)30375-3_bib14
  article-title: Differential experiences of Mexican policing by people who inject drugs residing in Tijuana and San Diego
  publication-title: Int J Drug Policy
  doi: 10.1016/j.drugpo.2016.12.010
– volume: 58
  start-page: 189
  year: 2000
  ident: 10.1016/S2214-109X(17)30375-3_bib22
  article-title: A comparison of the harms associated with the injection of heroin and amphetamines
  publication-title: Drug Alcohol Depend
  doi: 10.1016/S0376-8716(99)00102-7
– volume: 20
  start-page: 901
  year: 2006
  ident: 10.1016/S2214-109X(17)30375-3_bib20
  article-title: HIV incidence and factors associated with HIV acquisition among injection drug users in St Petersburg, Russia
  publication-title: AIDS
  doi: 10.1097/01.aids.0000218555.36661.9c
– volume: 388
  start-page: 1228
  year: 2016
  ident: 10.1016/S2214-109X(17)30375-3_bib4
  article-title: The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia
  publication-title: Lancet
  doi: 10.1016/S0140-6736(16)30856-X
– volume: 16
  start-page: 1385
  year: 2016
  ident: 10.1016/S2214-109X(17)30375-3_bib1
  article-title: Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(16)30325-5
– year: 2005
  ident: 10.1016/S2214-109X(17)30375-3_bib5
– volume: 58
  start-page: 1215
  year: 2013
  ident: 10.1016/S2214-109X(17)30375-3_bib15
  article-title: The incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis
  publication-title: Hepatology
  doi: 10.1002/hep.26387
– volume: 372
  start-page: 1733
  year: 2008
  ident: 10.1016/S2214-109X(17)30375-3_bib6
  article-title: Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review
  publication-title: Lancet
  doi: 10.1016/S0140-6736(08)61311-2
– volume: 43
  start-page: 648
  year: 2016
  ident: 10.1016/S2214-109X(17)30375-3_bib17
  article-title: Sex work as an emerging risk factor for human immunodeficiency virus seroconversion among people who inject drugs in the SurvUDI Network
  publication-title: Sex Transm Dis
  doi: 10.1097/OLQ.0000000000000504
– year: 2016
  ident: 10.1016/S2214-109X(17)30375-3_bib9
– year: 2001
  ident: 10.1016/S2214-109X(17)30375-3_bib38
– year: 2016
  ident: 10.1016/S2214-109X(17)30375-3_bib40
– volume: 388
  start-page: 1103
  year: 2016
  ident: 10.1016/S2214-109X(17)30375-3_bib42
  article-title: Clinical care of incarcerated people with HIV, viral hepatitis, or tuberculosis
  publication-title: Lancet
  doi: 10.1016/S0140-6736(16)30379-8
– volume: 388
  start-page: 1115
  year: 2016
  ident: 10.1016/S2214-109X(17)30375-3_bib43
  article-title: Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners
  publication-title: Lancet
  doi: 10.1016/S0140-6736(16)30769-3
– volume: 179
  start-page: 1383
  year: 2014
  ident: 10.1016/S2214-109X(17)30375-3_bib30
  article-title: Recapture or precapture? Fallibility of standard capture-recapture methods in the presence of referrals between sources
  publication-title: Am J Epidemiol
  doi: 10.1093/aje/kwu056
– year: 2014
  ident: 10.1016/S2214-109X(17)30375-3_bib11
– year: 2016
  ident: 10.1016/S2214-109X(17)30375-3_bib28
– volume: 167
  start-page: 166
  year: 2007
  ident: 10.1016/S2214-109X(17)30375-3_bib35
  article-title: Injection drug users in the united states, 1979–2002: an aging population
  publication-title: Arch Intern Med
  doi: 10.1001/archinte.167.2.166
– ident: 10.1016/S2214-109X(17)30375-3_bib32
– volume: 12
  start-page: e0177341
  year: 2017
  ident: 10.1016/S2214-109X(17)30375-3_bib13
  article-title: Risk factors for hepatitis C seropositivity among young people who inject drugs in New York City: implications for prevention
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0177341
– volume: 60
  start-page: 1829
  year: 2015
  ident: 10.1016/S2214-109X(17)30375-3_bib39
  article-title: Hepatitis C virus therapeutic development: in pursuit of “perfectovir”
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/civ197
– year: 2017
  ident: 10.1016/S2214-109X(17)30375-3_bib27
  article-title: A systematic review to estimate global, regional and national coverage of HIV prevention and treatment services for people who inject drugs
  publication-title: Lancet Glob Health
  doi: 10.1016/S2214-109X(17)30373-X
– year: 2014
  ident: 10.1016/S2214-109X(17)30375-3_bib41
– volume: LIV
  start-page: 15
  year: 2002
  ident: 10.1016/S2214-109X(17)30375-3_bib29
  article-title: Estimating the prevalence of problematic drug use: a review of methods and their application
  publication-title: Bull Narc
– reference: 29153723 - Lancet Glob Health. 2018 Jan;6(1):e36. doi: 10.1016/S2214-109X(17)30446-1.
– reference: 29132603 - Lancet Glob Health. 2017 Dec;5(12):e1162-e1163. doi: 10.1016/S2214-109X(17)30430-8.
SSID ssj0000993277
Score 2.644339
SecondaryResourceType review_article
Snippet Sharing of equipment used for injecting drug use (IDU) is a substantial cause of disease burden and a contributor to blood-borne virus transmission. We did a...
Background: Sharing of equipment used for injecting drug use (IDU) is a substantial cause of disease burden and a contributor to blood-borne virus...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
elsevier
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage e1192
SubjectTerms Global Health
Hepatitis B - epidemiology
Hepatitis B - transmission
Hepatitis C - epidemiology
Hepatitis C - transmission
HIV Infections - epidemiology
HIV Infections - transmission
Humans
Risk Factors
Sexual Behavior
Substance Abuse, Intravenous - complications
Substance Abuse, Intravenous - epidemiology
Substance Abuse, Intravenous - psychology
Title Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review
URI https://www.clinicalkey.com/#!/content/1-s2.0-S2214109X17303753
https://dx.doi.org/10.1016/S2214-109X(17)30375-3
https://www.ncbi.nlm.nih.gov/pubmed/29074409
https://www.proquest.com/docview/1957468702
https://pubmed.ncbi.nlm.nih.gov/PMC5683738
https://doaj.org/article/a8463239558a4e58a3933c2d2c439467
Volume 5
WOSCitedRecordID wos000414869500020&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: Directory of Open Access Journals (DOAJ)
  customDbUrl:
  eissn: 2214-109X
  dateEnd: 20231231
  omitProxy: false
  ssIdentifier: ssj0000993277
  issn: 2214-109X
  databaseCode: DOA
  dateStart: 20130101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2214-109X
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000993277
  issn: 2214-109X
  databaseCode: M~E
  dateStart: 20130101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELag4oCEEG_CozISB5AIXT8SJ9xo1Wo5UCEB1d4sPybtIkiq3S7c-EP8ScZ2Nt3AYTkgRT4ksS1nJuPP9sw3hDyvmbATYD73cbfKC5NbayAPXO0OjDS1ncRkE-r4uJrN6g8bqb6CT1iiB04fbs_gBCm4qIuiMhKwELgEd9xzF2I6yxhHjqhnYzH1JeEewWPaRc6ZRFtTzy7Dd_Y-DjdfMPVShDSwuRhNTJG_fzQ__Y0__3Sj3JiXjm6Rmz2gpG_TQG6TK9DeITfSbhxNQUZ3ya9E7U_PF4HdO_zMtGvovA2bMDh3Ub9YndLVEqhpPQ3y6jx8S2TW2IobkzrHl8YtTd-dvKLTfSzCs-nBCbZNk3M6_XHW9T3FbpZvqKHRjRFx6SnQSyppmsJo7pHPR4efDqZ5n6Yhd2UhLnIrWIlIgTlgUjWiBFE2dW2ddZUyKARQk8YpY4AJwMVMYwAvKy14VRUNGoD7ZKftWnhIKJ_UxpsKpVs2iDSMqZzzqnFSGm-lg4zItYy06znMQyqNr3pwVguiDcfqM82UjqLVIiOvh2rnicRjW4X9oADDy4GDO95AzdS9ZuptmpmRcq0-eh3mioYZG5pv670aKvY4KOGbf6n6bK2nGu1EOPwxLXSrpWZ1oWSJ1pln5EHS22F4POyQ4EI_I2qk0aPxj5-087PIRV6UVeDGevQ_Pthjcp0H0BSdhZ6QnYvFCp6Sa-47auRil1xVs2o3_uZYvv95-BuP6FKN
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Global+prevalence+of+injecting+drug+use+and+sociodemographic+characteristics+and+prevalence+of+HIV%2C+HBV%2C+and+HCV+in+people+who+inject+drugs%3A+a+multistage+systematic+review&rft.jtitle=The+Lancet+global+health&rft.au=Degenhardt%2C+Louisa&rft.au=Peacock%2C+Amy&rft.au=Colledge%2C+Samantha&rft.au=Leung%2C+Janni&rft.date=2017-12-01&rft.pub=Elsevier+Ltd&rft.issn=2214-109X&rft.eissn=2214-109X&rft.volume=5&rft.issue=12&rft.spage=e1192&rft.epage=e1207&rft_id=info:doi/10.1016%2FS2214-109X%2817%2930375-3&rft.externalDocID=S2214109X17303753
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2214-109X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2214-109X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2214-109X&client=summon